<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1-90-82
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1982
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PRIMPERAN TAB 10MG
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        METOCLOPRAMIDE HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        6.7
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="sanofi-aventis" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            sanofi-aventis
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2218]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Sanofi Arabia Trading Co. Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            sanofi-aventis
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A03FA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Primperan is an antiemetic. It contains a medicinal product known as &quot;metoclopramide&quot;. It acts on part of the brain to prevent nausea and vomiting.<br />Adult population<br />Primperan is used in adults to:<br />- prevent delayed nausea and vomiting that may occur after chemotherapy,<br />- prevent nausea and vomiting caused by radiotherapy,<br />- treat nausea and vomiting, including nausea and vomiting which may occur with migraine.<br />In the event of migraine, metoclopramide can be taken with oral painkillers to help the painkillers work more effectively.<br />Pediatric population<br />Primperan is indicated in children (aged 1 to 18 years) if other treatment does not work or cannot be used to prevent delayed nausea and vomiting that may occur after chemotherapy.<br />Primperan 10 mg tablets is not suitable for use in children weighing less than 30 kg. Other pharmaceutical forms (for example, oral solution) should be used.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>If your doctor has informed you that you are intolerant to certain sugars, contact him or her before taking this medicine.<br />Contraindications:<br />Do not take Primperan if:<br />- you are allergic to metoclopramide or any of the other ingredients of this medicine (listed in Section 6).<br />- you have bleeding, obstruction or a tear in the stomach or gut.<br />- you have or may have a rare tumor of the adrenal gland, which sits near the kidney (pheochromocytoma).<br />- you have ever had involuntary muscle spasms (tardive dyskinesia), when you have been treated with a medicine.<br />- you have epilepsy,<br />- you have Parkinson&#39;s disease.<br />- you are taking levodopa (a medicine used for Parkinson&#39;s disease) or dopamine agonists (see Section &quot;Taking or using other medicines&quot;).<br />- you have abnormal levels of a blood pigment (methemoglobinemia) in your blood, or have NADH-cytochrome b5 deficiency,<br />Do not give Primperan 10 mg tablets to children under 1 year of age (see &quot;Children and adolescents&quot; below).<br />Other pharmaceutical forms (for example, oral solution) should be used in children weighing less than 30 kg.<br />Do not take Primperan 10 mg tablets in the cases described above.<br />If you are unsure, talk to your doctor or pharmacist before taking Primperan<br />Appropriate precautions for use; special warnings:<br />Ask your doctor or pharmacist for advice before taking Primperan if:<br />- you have a history of abnormal heart beat (QT interval prolongation) or any other heart problems,<br />- you have abnormal levels of mineral salts, such as potassium, sodium, and magnesium in your blood,<br />- you are taking other medicines known to affect the way your heart beats,<br />- you have a neurological (brain) disorder,<br />- you have liver or kidney problems. The dose may be reduced in such cases (see Section 3).<br />Your doctor may prescribe blood tests for you, to check your blood pigment levels. If abnormal levels are observed (methemoglobinemia), treatment will be immediately and permanently discontinued.<br />You must wait at least 6 hours between each dose, even if vomiting or rejection of the dose occurs, in order to avoid overdose.<br />Treatment must not last more than 3 months due to the risk of involuntary muscle spasms.<br />Children and adolescents<br />Abnormal movements (extrapyramidal disorders) may occur in children and young adults. This medicine must not be used in children under 1 year of age due to the increased risk of abnormal movements (see &quot;Do not take Primperan if&quot;).<br />Primperan is not suitable for use in children weighing less than 30 kg. Other pharmaceutical forms (for example, oral solution) should be used.<br />Use of this medicine is not recommended in patients with galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption syndrome (rare hereditary diseases).<br />Taking or using other medicines<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.<br />This is because Primperan can affect how other medicines work. Likewise, some medicines can affect the way Primperan works.<br />These medicines include the following:<br />- levodopa or other medicines used for Parkinson&#39;s disease (see Section &quot;Do not take Primperan if&quot;),<br />- anticholinergic agents (medicines used to relieve stomach cramps or spasms),<br />- morphine derivatives (medicines used to treat severe pain),<br />- sedative medicines,<br />- medicines used to treat mental health problems,<br />- digoxin (medicine used to treat heart failure),<br />- cyclosporin (medicine used to treat certain problems with the immune system),<br />- mivacurium and suxamethonium (medicines used during anesthesia to relax muscles),<br />- fluoxetine and paroxetine (medicines used to treat depression).<br />Food and drink<br />Alcohol should not be consumed during treatment because it can increase the sedative effect of Primperan.<br />Pregnancy and breast-feeding<br />If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. If necessary, Primperan may be taken during pregnancy. Your doctor will decide whether you should take this medicine.<br />Primperan is not recommended if you are breast-feeding because metoclopramide passes into breast milk and may affect your baby.<br />Driving and using machines<br />You may feel drowsy, dizzy or experience abnormal spasmodic movements and generalized spasms distorting your body after taking Primperan. This may affect your vision and your ability to drive and use machines.<br />Primperan 10 mg scored tablets contains lactose.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.<br />Dosage<br />All indications (adult patients)<br />The recommended dose is 10 mg, up to 3 times per day. The maximum recommended daily dose is 30 mg or 0.5 mg/kg.<br />The maximum recommended treatment duration is 5 days.<br />Prevention of delayed nausea and vomiting that may occur after chemotherapy (children aged 1 to 18 years)<br />The recommended dose is 0.1 to 0.15 mg/kg, up to 3 times per day, taken by mouth.<br />The maximum daily dose is 0.5 mg/kg.<br />Dosing table</p><p><img alt="" width="409" height="169" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZkAAACpCAYAAAD5qEDXAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAADsMAAA7DAcdvqGQAAC0wSURBVHhe7Z1NrizNVp49FFsMApiB8QhsTwAkunbDPbvhJkKiCRJdu+H2FX0QA7hiACDaIGbwWc+t8+i8Wt+KrKq9KyuzqtYjhTIy/jLijRUrIuvo5P53vwzDMAzDTswmMwzDMOzGbDLDMAzDbvxqk/m9f/8ffsSGexjdjmX0vzA6DEdTbbDdZCZMmDBhwoSvhmTeZB7E6HYso/+F0WE4mtlkdmJ0O5bR/8LoMBzNbDI7Mbody+h/YXQYjmY2mZ14Bd1+85u/+eUv/+qvf9y9F2O3F0aH4Wi+tcn8xz/6T7/88Z/86Y+7Iel0Qy/SCcT/5//63z9ybsN6j+I//5f/+rs2//Gf/vlHyq+xz6/GtT6zwVLGgB3/y7/+24/c9+GWuata/Nmf/8WPnGH4PtUG79pk/uD3//ChTu+d6HTTYePUdfD3vElQ/pF6/5//+/+ubnSrTebsm8+1vulYGQfzQfy//ff/8SP3fbhljlKLYXg01QZv3mR++9t/+F0eYesk/Kl0uqVjxrkTv+fUSPlHO4Jrp/fVZrJKPwvX+lYd69nH81VuGdNsMsOeVBu8eZPhFEweASMVfnbAWA1/+3d//ztHZvq9PxG9Kp1ujN90Ts3EfZPpNCLNNx7yuJJvnM2d+qTZHpBPGx4EoGs/+wPmG5g7y3jleWyMxE0/IzmujtUmoy2vbFadPRyc3bav6QCrTYY0xssvFpTpxoqNkU/QFoGrz844UBe7JlAfbNO28C/AM9WcZ3NNux/OT8493LzJsMgwBvJdcEw89zo3DVFDNT03pXel0y0Xm4uMRQRoRL4aoaV6ck1HYDppaIz+On42BtqlHPnEbb/OQfZnNXeWIZ22aCPTz8q1vqWe4HhIh635wMnlvJ3ZtunTNaoWQhpjwxZ09nWsOH7T0iZW8bRd2qM+kJZ6m86zuceuO7sfzg9zlty8yWAQGEkahI4OuFIGdHpA+icYR6ebi01tWDTCfWqEtuor1tMpoCP3nPpM8w2ThU/7tAHdHHBPHFZzl2VW8TNyrW/qVcdJuvfmkY6OOjlP2XB226ZP11ALg2Mg7thgZUOmcSV9K+6mASubyzhX453dD+fHOZabNxmdWBqE98A1TymUpxzxsy3EPVCHxPGDG4gbDXF1NJ7loZbJU6T/eE0+zoB4nva4r3OQ7a/mLsus4mfkWt+ubTKZZxyN0ZBA3Lwz2zZ9ukbVQmpaN9YsY/otca6ZbtpWHLhPux/Oj3MsN20yvtL600yW8bTD1Z8UyE9D+QQ63dDA9LpAu3iWhyxjvvegA7BtQuc0hftsv5u7LLOKn5FrfVttMjquzMu4m7FviJl3RujfNe7ZZLbKcPV5t8STbGcVB+KG4TWo833TJqNRZtCZ4aAqOq9PotMNDUzvToHGSecthBNbtpPlre8bB9g+c2HcE3c3B5aRbu6yzCp+Rq71rTpWxs4mLaSbRznmQ/JnzLPb9i1zdOsm043Vgw1w9XmruD+XaZeSz8o417TLzu6Hc+Pcy02bDBPtxHuy82cfjE4joRxoWLz5uBm9O51uudjQL3XDcZHvWyLpLig0899aXHzeWx8sD/6kIN0cZH+gm7sss4qfkWt9S8eq5o4Zuvng7c5/ACcPzm7b13SA1CKpad1Y86cr7cd04qTThuk+Sz1pC0jzWRl3Q6cc5Tu7H84N85XctMlgQEw+aDTec8UYNTiNSafKlft3p9PNxUYgnk6Nk5356GeaOqKb2ppHejo2tHZx0rZx6ObA50k3d1km4yx2ytHWGclxdWi3Bu1XuvlwzKTjPOHstk2/rqEWjCupad1Y3Vwop17gZkAe+mU72CbpBDeLfFbG85nU6+x+ODfMV3LzP/x3YDAYBGAQGsYnco9uX+WRz3i3uXuG/q/AM3XITWZPZm5fizpf39pkcEqeQDi9UNfX4U9j74XASdFN4RG829ztrf+r8EwdnrHJPNruh/2pNvGtTYZXW35KwwgIGMSnsvdiy5/OHsG7zd0zneuZeaYOz9hkHm33w/5Um/jWJjP8ZHQ7ltH/wugwHM1sMjsxuh3L6H9hdBiOZjaZnRjdjmX0vzA6DEczm8xOjG7HMvpfGB2Go5lNZidGt2MZ/S+MDsPRzCazE6PbsYz+F0aH4Whmk9mJ0e1YRv8Lo8NwNLPJ7MTodiyj/4XRYTia2WR2YnQ7ltH/wugwHM1sMjsxuh3L6H9hdBiOZjaZnRjdjmX0vzA6DEczm8xOjG7HMvpfGB2Go5lNZidGt2MZ/S+MDsPRzCazE6PbsYz+F0aH4Whu2mQmTJgwYcKEr4Zk3mQexOh2LKP/hdFhOJrZZHZidDuW0f/C6DAczWwyOzG6Hcvof2F0GI5mNpmdOJNu9OU3v/mbH3efwdjthVfVgT+z/I//9M8/7o6H9TM29TWqbndtMn/5V3+9mc/f4v6D3//D34Vxchd++9t/+JUeLCb+rj5/I/3a3y/f0pz6nc6Uf/W/2X8v9+j/zmytz2eRfuCWv8//L//6b6ezWfpyBi1fkarbzZsMJw2MZkt4FjSwoHGAn0SnizqQlwuIDYbNA8hfLa4tzf/27/7+V+3KKv2duUf/d6bT4bug4z3tph+gHtdKbRN7PhPYyx5afgJVt5s2GQT/sz//i7uEpxwnlE+h6sLY//hP/vR3by3k6eRYgNz70wAbCeUq1zSnTrabrNLfmarRSv8VlE97fVXb7WzlFur4k5UN3gL1ureZW9o8ck6+M+ZPp+p2189l9whPuWoUGJtvOOTZFqcYfz7SGeQpNI2UexwzVxwIjpi4bwZH4Vg6yMtxZVn6ryYdneaMe+uEnuno6kkSjXC8/pTxzEW7N1WjZKUToKM2ZDk0yzrohG6md4eCs0D/OkjXDjLO+FlfpGETHn7EQ5EBLViv1CPYzgrqoG/Stck1+3RtTkB/Qp793vIHlNf2u347z9T3CpTlOdzThs8F+z78pOqxyybDpHQL0foaKsZB3EnX+EgjztWTqK/TxKnHvXlcKXsk9GMFeS6O+m8s9b7Sac5Csl4uOjGd4DygD+lcqctCeSe2NFzpBOTppNDEsmisI0FDN2Xysc2zstIhNahxxg9cOcBVKGu7aOB6ZQ2Svlp7lCG/0yvbBOK1T1tzgg3bb8owR9f8gT6EuoyhQvukUz83meqL7Dtp+rHhJ+omD91kEN0dHwOruIkwMTo6DVGjMD8hLQ2QumB7TP7R0I8V2X/6nmXrfaXTHI3RK9tNSKddyqkNmrqwqNMdAl6ZLQ1XOkHmpdYZ56peW22dAftcyX7XuOuJ9agTT1KLXK/aYF3r6QdosyPbBOJd/7JcxnHstk06tn2rP8h2kmxztS5JMy/92PCTqtuXNxkmlHtDQp4nggrpnBg4MVHPCcMoNcw0WsqS5jMyDtQ5wySrS0f2uRqv9ys9iWd5tPG0me0mpKMzbYtzAtTpTqyvTGpUWekEmZdaZxzdPK1utXUG7HMl+72KV9uU1KKWIZ52luj0u/xsE4h3fcpyGefKvLD+uZp+zR/gk5hLyye5Zmr/IH0RZdOPDT+pun15k9HYDHVD4eTXiU86gYnGCKvRCqchyphvWxkHThOk1befZ9ONQbLPdbzer/RMzQHtHCvpnca24elbWBi0+44LIzWqrHSCzEutM47TQjudZnd4Ogv2uZLjXMVXazG1qGWIk7YCG0S7SrYJxLs+ZbmMc+2eu+UPOKC5CdlOkm3mszpfVP3Y8JOq7W7/8I8j64yANIxOw7NNJjKhvqdtJ7bGBaNhso9kS5fsc9WQ0xCGv6KWJ15D1Y40tOOaCwDtz/Lm92gY6wryqs1I5qXWGdfJoF39aehsrHTIca7irs1KaqGjFeLdOhftsJJtAvGuT1ku4/STtdPR+QPmkDpsPvXZQppjyTKdL1KrTq9Pp2q72ybDJHcL0pOGp2zv62mANJ6HcRjP9MQ2jmTr+dnnehpOA+7Y0jzbTUzHKWbbxFkc3Snv1VlpBCudIPNS64xjx5Y781sM2OdKjrPGdazYR3dY67RgXbo2tzZeN+dKtgnEu/5luYz7JtHR+QP7DfXZkgcwNLEMV+qkL6p+bPhJ1fahm4zOC0fKDs+kVJyoPIXk5NqGJ5Vc4JBxYNFz3y2OZ7KlS+0z48WI0YJxbi3SLc1ru2K6dXWMLhzCuy0OxrRCPToyT71qHP2YJ+632joD9rniGnNcjoE4tuCa7d4O0kG7flmnpHfrPP0AZd3EkmwTiGefjNvfVZxn8HyusPIHbgrks5naTkI6OlGG+pbpfFHnx4YLVdu7NplqGBWMlXwmSkPrYAJpSzAQ6lDXk7dGRDrluQfSrIsxkI8RbD3vGWzpkn0G+up4rxnplua1Xcl0nuMGjo5oRkAzF+Y7sNIIVjpB5qXWGWeOdFpoiXZnZaWD64k1muvPNK91wwDSXGfEqcs9oVt3tqdz7qhtUj77ZDznIeNA29QnML5r/iDHSbk6VtcFZZhnysDKF6WOw09yjuCuTeZRdBPccUuZs/AM3b4Di47FJcSP3pgfyZ7607YbtQ7nrGz1rVtPlNdpfgJsJFugUadTl3arH/s0qg0+fZPxreXdOLPjAXT31Eh4twWyp/6eYIHNxrftM3KvDpT/pE3mUbyrH3sE1QafvsnwinvmRfpV9tbtEfjzAovj3V7z99Sf0y9vfmjH9cyb8706UH5+8rmfd/Vjj6Da4CE/l70jo9uxjP4XRofhaGaT2YnR7VhG/wujw3A0s8nsxOh2LKP/hdFhOJrZZHZidDuW0f/C6DAczWwyOzG6Hcvof2F0GI7mpk1mwoQJEyZM+GpI5k3mQYxuxzL6XxgdhqOZTWYnRrdjGf0vjA7D0cwmsxOj27GM/hdGh+FoZpPZidHtWEb/C6PDcDSzyezEmXSjL5/2qZCx2wuvqgOfaLn28cpnUr/4PNxO1e2mTYbJ5wOB5HFdGQP5Gbq/I/GuMN4OP0yZTr/qtEX+8STgu1ksSL4/xrX7jhblP+2jh52O6EM6+n+KLV6zp2fgn0Mg+PXqLbDhs9ns2b+2fWaqbje/yfi3R/hAYH4yPtFQDNb5BDrd2FjYDNRFUqetNw6cJAs128ZZqj8bfuc86/M+gU5//5QBWpD/Tn/aYEWnw3e591TvurdeZ+O1zbPNjTYz3E/V7e6fy7bE/+RJqWPndMZmwFsfeen0b9GJ8nzpteqdGwv5foI+qc/7BK5pSv7W2wzzlW+F3RviK3CLbXXU8Sdba/4a1OveZm5p88g5+c6YP52q25c2GU7XHdfqYmz+DQYMxvKcYnCW5OkcOen4FpBGyr0/g+DAcbTEj/45xLF0kOe4YKtspRp7tsWYu7nIMujqSZLybHz+lPHMRbs31zQlv7MRbEwbUjc0Sw3RCd1MX73JnwH610G6dpBxxs/6Ig2bqD+F81ZCngEtWK/UI9jOCuqgb9K1yTX7dG1OQH9Cnv3e8geU1/a7fjvP1PcKlOU53NOGzwX7Pvyk6nH3JoP4iNxBXSexK4OBUEZDxTiIO+kaH2nEufom4Os0cepxbx5Xyh4J/VhBXi4O7hkzhuq4VqiZZFsspO65liHoENGHdK7UW83hq9LpIGhMvj/jJKTrpNBE7XBWOhI0ZL7UsGvnLKx0cFxdnPEDVw5wFcraLhq4XtV1tfYoQ36nV7YJxGuftuYEG7bflGGOrvkD1xp1GUOF9kmnfm4y1RfZd9Jo034MF9RNbt5kEJYJcBI6nEQmhXJMWkI67VNOR6chahTmJ6SlAVIXbG/Vn2dCP1Zk/8HxadSrRQoatLDIHL8LsEIaZSirNjyTZwFtuvm8C1v664Q6cm5S64xztX6WPyP2uZL9rvG0J514klrkeiUQJy0hnXbIo82ObBOId/3LchnHsds26dj2rf4g20myTTTpypBmXvqx4SdVt7vfZDxNMKFMlqGyMlg3H05M1HPCKKthptFSljSfkXGgzhkmeUu32mfJRbrSk3i2zVhxeLmQK6Shs84DaD83me7E+sp0OoAa14OLkKfeqXXG0c3TapY/I/a5kv1exVeONbWoZYinnSU6/S4/2wTiXZ+yXMa5Mi+sAa6mX/MHbEDMpeWTXDO1f5C+iLLpx4afVN3u3mSYJMpobIZ6eqjGKDhIAhONEa7K4RwoY74TmXHAeZC2ciLPohuD1D4n5DHGlZ7U417UBSNHR64V2/D0LZSl3XdcGKlRgiOoOiTUU4vUOuM4LbTTaVZbPxMrHXKcq/hqLaYWtQxx0lasbDTbBOJdn7Jcxrl2z93yBxzm3IRsJ8k281mdL2JcBP3Y8JOq7d2bjCdDjWAFE9IZl+nmOZm0m+AIPW3n87pnYzRM9pFs6balF3ndYhH16cCBduOmPNpxzQXAc87y5vdoOo2wKexsa1OgnnOTWmdcJ4N29aehs9HpADnOVXy1ZlMLyuQziG/Zr3ZYyTaBeNenLJdx+on9d3T+QFtg86nPFtIcS5bpfJFadXp9OlXbL7/JXHtzcJeveNLwdOl9PQ2QxmTWTS3jYhtHsvX8rs/gyXhLS+qt2kbDbqH5PJyiiwOIsziuzd0r0mmEs1k5Ism5Sa0zzsZiuTO/xUCnA+Q4a1zHin10a7bTgnXp2tzaeN2cK9kmEO/6l+Uy7ptER+cP7DfUZ0sewNDEMlypk77IZ6z68MlUbW/aZFhYLi4WbWc0TIDOywnojM+JysWfk2sbnlRygUPGgX5x3y2OZ9LpJtnn1Ikxd1om1Mu2qQ9q3Dk9n2ddy7hwCO+2OBhTwphTB0L3s4ZlQL1qnLawR+6z/BmxzxXXmONyDMSxBbRxzVXSQbt+sT/SqaNNivbtIcpNLMk2gXj2ybj9XcV5Bs93blf+INcLm6ntJKSjE2Wob5nOF6lDp9enU7W9aZNhghCfPMRnEio5MZTtDEsox4QJBmL7nrw1ItIpzz2QZl2eST5GoGEfBf1aUfusTistk7oYU5fUMMnnUc4N3OcR0MyF+Q6kRpAbqkEdEtLVKrXOOI4E7YA20O6s2OeKdsOGwlgcs2le64YBpLnOiFOXe0K37mxP59xR26R89sl4zkPGgbapT2B81/xBjpNydayuC8rkAXDli1LH4Sc5R3D3z2WPoJvgjlvKnIVn6PYdWHQsLiF+9Mb8SPbUn7bdoHQ4Z2Wrb916orxO8xO4dqhDo06nLu1WP/ZpVBt8+ibjW8u7cWbHA+juqZHwbgtkT/09wQKbjW/bZ+ReHSj/SZvMo3hXP/YIqg0+fZPhFffMi/Sr7K3bI/DnBRbHu73m76k/p1/e/NCO65k353t1oPz85HM/7+rHHkG1wUN+LntHRrdjGf0vjA7D0cwmsxOj27GM/hdGh+FoZpPZidHtWEb/C6PDcDSzyezE6HYso/+F0WE4mtlkdmJ0O5bR/8LoMBzNTZvMhAkTJkyY8NWQzJvMgxjdjmX0vzA6DEczm8xOjG7HMvpfGB2Go5lNZidGt2MZ/S+MDsPRzCazE2fSrX5I8BMYu73wqjrwv+evfVfsmXziGnoUVbebNxnSM6zgo4t85+kdP12yRacJC4d0PkeSX6VGI/QhbH2kcqv+lsZn/4jjHtyjf0J+hlfnDGPwS9UEPyy6BZ/pod9n+obaJ66hR1F1u2uTQXjC1uah48MRYmTv9BHGLTrd3EA0WO/ViIBGK67VX2n8iQvkHv0T0sknbNn1q7DHvKPLPe36JySs1+la2+zm5kg+cQ09iqrbXZvMNTAuyuH0PJ2czXj24po+5HOaViN+GiDcqlGtv6XxbDK/Rv0q9+iUP+fUjf0sfHXetaeO79gT9bq3mVvarH16puazyXydqttDN5l6OiHOZAnGxikcMJgsax4/A7mY87Xb0xBXyvE1XAL35BM/kmv6kI+Tq8ZbNVph/WsaQz7DT5KjN/X9mnD3BvTKpCYd6le5Vg+9tTXKcqUd43IWbVfjId01lHFsg3VGGv2u/y7iocbAuDjUUI9gOyuoU/9wWdcm1+wTdczHnvELxqXzGdbr5rrzJwn9yHnmCpTlOdzThs8F+z78pOpx1ybD5CDu6uSdzg2I52Sbr6FiHEAZ40ygi9fnkM+zwTYwJh0oRkCbR5LjrjAO8ukvY8myxLsFkWT9axpDlkFX9SGNK+XR+Z1ITSqpX4X0LbtWSzSzHezTONczaUs/OkhnLF3ctce1+3x92hNj1EmrAWkdlCG/0z3bBOK1T2wcaGkea17njs7VZ1Cesly7Pjm/1NWfJLRPOvVzk6H/tGf79p002rQfwwV1k5s3GSfIiVhNouITiDOhwmSRRrlcjEyScSawGkAaZE4waPBHY/86XATAuLMs8dSoI+tf0xjUiKtOg3rqSrrtvQupaSX1q1yz67Q9UNeMn0nblQ5dv41rP+ikE08oa7tuHGl/df2RTjvkua4r2SYQ7/qX5TLe+Qz9C5vBFtlOkm3WdSqkmVf92HCh6nbzJiPp2Jgsg3k6fSdSAxbyWdA4P+tRjnQMk2v2AYNh8k2zXVktjGeTfUrUS2dWjZd4p6XU+rdobDrlXHAsQO6B/O7E+sqkpknVb4XlqsNUSyHuHBk/k7bZ16Trd41X2xTyTV/Zb4dOv8vPNoF416csl3GuaF59BvdbTr/6k4R27GvtH+C3SCOPstWPDReqbndvMkAZjc2gM2ORMgGc5kivE0A6gYnGCMH2KrSl0VAG6uTrdJnwI8k+JfQrT7bqJo6dqyFPYrU+XNNYjWoedWj7HRcGY+3o9FtBG9UOq72lphk/i7YrHVb9zni1TSHf9JX9rkB7tKlkm0C861OWyzjX7rkcJsjrDhWdP0myzXwWPgZ/5djJY1yE9GPDharttzaZa1CuTjb1MLo0POJ1k3DzoP7K0MQ06hxF7RM4htw0av+J19OzdPUr1K8a+wwcHotA0P7aSe9VuVX/LWij2nU3X6TV+Fm07XSAVb/rGNCrQr7tUiafQbxqlmCDWV6yTSDe9SnLZZx+rg6WzEHaPaz8SUKaY8kyjIEApJGnVp1en07V9u5Nxlfg7qSQkE+56vhNz9Olp4IEx2tfVoaWkHatT3vS9QljrwvB8eP4CMRXJ6GufrLSWI2cKzcxFgqL40id9oJxVq7pl6zsutobcdJq/CzadjrAqt/EdayMoTpnSA1cl9gcgfjqkAS0x+ZbyTaBeNe/LJfxzmeI6yJZ+ZMkDwloYhmu1HG8xH3Gqg+fTNX2pk0GcV08TEJnNKLDy90/caJy8TvpLHTyuTqJOGLasV/VQNJZ++wjyD6BfaK/BjcTTj/cY8grLbfqX9OYsvYnF6MLh/Bui8Pxyko/tGPs5BO/ZtepJdhmjZ9F2+xrogN1PDkG+os2q7eDdNBoRhzdSKdOXXdqSpuUdRNLsk0g3ulqf1dx59S1wbySVzfLlT9JSEcnylDfMupin2lfHW49xHwSVdubNpkUnSv3KzBYynGtxie0wYQlTBaTqQOGbIvJp71qnJbpDPmZZJ8gnY7BUxIGzzgZkwuyslX/msapkYuLRejcEXi+C/MdcLyy0g+90E0drtl15wy13YyfRdvsa6JTZuy5/kzz2tkTadgq43INcr+yX9uj/MoJ1zYp3+nKlfsah+oz0N42t/rFlXJ1rM4dZfLQoXbco53+KXUcfpJzBF/6N5nv0k3wim7hn5Fn6PYdWHQsLiG+2uBekSP1P5O2Wzp0a47yOs1P4Jo/QaNOpy7tHj/2SVQbfPomwwnPE8I7caSTuwV099RIeLcFcqT+Z9L2Xh0o/0mbzKN4Vz/2CKoNPn2T4RW3+3eEV+dIJ3cr/rzA4ni31/yj9T+LtvfqQPn5yed+3tWPPYJqg4f8XPaOjG7HMvpfGB2Go5lNZidGt2MZ/S+MDsPRzCazE6PbsYz+F0aH4Whmk9mJ0e1YRv8Lo8NwNLPJ7MTodiyj/4XRYTia2WR2YnQ7ltH/wugwHM1Nm8yECRMmTJjw1ZDMm8yDGN2OZfS/MDoMRzObzE6Mbscy+l8YHYajmU1mJ0a3Yxn9L4wOw9HMJrMTZ9Ktfq32Exi7vfCqOvCJljN9DPcT19CjqLrdvMnwVVk+bX3Lt5n8zLrwsUD/VoOfRH83Ot34XDjfsyKkZmiJFoRrX+ulHuVoww8ZXqvvp8k/iW68pGU4+s9BPINOh2eTdu+fp9gC/0C/z/Shzk9cQ4+i6nbzJoNDw+Hh1DCe1Vdm2UzIz3b4mJyfQsfo8rPo70Knm39TxI1C1JKAVivYjGnXjUTNr9WfTeYCaWhhcD7emT3mHTu7p920e+pxrdQ2rx22ns1sMl+n6nbTJoPRkI6T89SxOkGzodQJYlMhHd518q6NSf3Ukg2kbiKV3JzllvqfuEC68d6jgbYtGX8lvjrvdfzJd+yJet3bzC1tHjknn7iGHkXV7aZNpp46iDMJK+oE4Sj9qYK8evrGCD3pY0jWxXn6E53Py1dxT0hcKcNzCNTjnnae9RNJjreDfMZWtSG+0pKxuznLLfWzDJsSWvBstEAf9Xvmot2b1ES6tAraoDFl1RLdjQM6oZvpxM/Kasyku14yzvhZU6RhExxcEg81BrRwfRFsZwV1qg13bXLNPl2bE9BvkGe/rdet+853JM4z9b0CZXkO97Thc8G+Dz+pety0yaTTAuJbzruW17mBk5RYXgPGaIhrDBql+UCb5IP1MTCdqv2jzjPI8VYYg+OnX1mW+EpLxkc9rmpyS/3Un3o8n7qk2Uadg1cnNRHS0I6wGi9ldFKU4R79sCUdiXOghtjYWel0AMfVxRk/cO3+RkraExqgBTbFWiSdtA7KkN/plW0C8dqnrTnBhu03ZZgj3+y5dn3qfEdC+6RTn/bsH/2nPdu376Tpr4afqJvctMmkMRGIV8eWVAMCjIMJdBITNxGeowPUQDUW8yWfkZMOPGOrf3tgXxL6w7jJYzxAv7Is8VVfyaM+7WD06HJLffXgqtNAOxcW6bT3TqQmor1gX4wdJ1JRJ1C3GueqXln+jNjnSva7xrUf7EsnnqQWuS4JxLVtSbunzY5sE4h3/ctyGcex2zbpzK9+pPqXSraTZJt1nQlp5qW/Gn5Sdbtpk8FomESMyQlCXOKGpE4iZV2kTEjn4HQCOEXqO5EYa3XUGBEG4TPq83hGln8G+fyKTo5+Oy4hvtKSvDR6dFjVT9TDZ4J9APK7E+srk5p0oGPnQKmn5upW4+jmaTXLn5GVDtnvVbzalqQWt9if6PS7/GwTiHd9ynIZ58q8MKdcTed+y+lX35HQjn2t/QP8E2nkUTb91fCTqttNmwzgsBGWDYIyGpshTw91gnSOwO5PHhtXQrsEDADjtP0K/dCQzK/Py5MUbT2Drq8JY6OfdVzEV1qaB45xVT+xLIG4MH+0/Y4LIzXpqLpJaqRuNY6toZ1OM239bHRjhBznKr7SKLW4xf4S7B7tKtkmEO/6lOUyzrV7rv7Ft9ik8x1JtpnPwp/glxw7edVfDT+p2t68ySSU6SZRcoLAiQGNoC5UJhBj1CBtIzcj36hoI59RnwduNBjCM6jPr+DYGWOnzeqNKzdn691S3zI80xM40JaL7N1ITTq0r4qaQmqbcZ0M2q3m6iysdMhxruIrjVILyuQziGujHdhglpdsE4h3fcpyGaef3c+fgH2n3cPKdySkOZYswxgIQBp5atXp9elUbe/eZNwk0vlX6iQyEaTBqr7pbgre5ymBBW67+Yz6PMnye3PtORg9/XFcbLIE4quTEFq4kDBq2rilvnp48tYxutHRxrvBOLfw1Fmhnra5sintiLR6ODobKx1ynDWuY62HEum0YP0SiGtfHbTH5lzJNoF4178sl3Hmc3WAdI0k9hvqsyUPYGhiGa7UcbzEfcaqD59M1fbmTcZNIXf1FXUSmTjrdKcMcALzdJKTzqSmg6U9n1GfpyPQMT+DfL7ozHH2bLRq6KZL/7oFKJSx/xizzuBa/dQjF6MLh/Bui6Pqj9bqr910zpB09ILULePYE5pzn+XPiH2uuJYcl2Mgji1oo93bQTpo1ymakp52LWn3lNVuk2wTiGefjNvfVZxn8HyuwFyRV9e9NlB9R0I6OlGG+pZRF/tM++qwepv6ZKq2N28yGCJ5XKtRVaoBUZ56TBZXN4EKE0tdwXCYdNpyk8p+kEfb9XmWoT2Nb2/y+WI/6KcLD4ijRU3vwDFQlvGr+7X6qQf5xNEBPdCeQP1nafMMqv7pKNCpc3RAvjaXumUcR0Jb4HyclaqD6JSxyVxnpnnt1jZpaMi4XW/cr+zP9ii/csK1Tcpnn4znPGQcaJv6BMbHnNvmVr+4Uq6O1XVBGeaZMqB23KMd95A6Dj/JOYIv/ZvMXnQT34ExnI0jdbsFFh2LS4h3C/FV2VN/2vaNWodzVrb61q0tyus0P4FrvgONOp26tFv91adRbfA0m4xvLa/KmR0PoK+nRsK7LZA99fcEC2w2vlWfkXt1oPwnbTKP4tX91Z5UGzzNJsOr75kX7zWO0u0e/HmBxfFur/l76s/plzc/tON65s35Xh0oPz/53M+r+6s9qTZ4qp/LXpnR7VhG/wujw3A0s8nsxOh2LKP/hdFhOJrZZHZidDuW0f/C6DAczWwyOzG6Hcvof2F0GI5mNpmdGN2OZfS/MDoMRzObzE6Mbscy+l8YHYajuWmTmTBhwoQJE74aknmTeRCj27GM/hdGh+FoZpPZidHtWEb/C6PDcDSzyezE6HYso/+F0WE4mtlkduKVdKOv81mZ9+RVdeATLWf68G394vNwO1W3uzYZ/x5Jwr1h9Tl18AON6dwwKj48yLe0tuq+Alu67QXf0OJbWjw7v7Ccfx6gg/Lv9lHElf7X7M6vK78LR9hhRfsj3KIvdnw2mzz717bPTNXt5k0Gh4XR1HyNg8CC7mCBs6AtK6TxoTn/5smZjOxeVrrtCXPi5uIpUK2Ba6fpq2vd0em/sjs2GA81K41elT3sEB3vaVc/YD2uldrm2f7sBDaxh5afQNXtpk0GwdkMOuGvTYSnbZwgZV3QeW88T+OvxjUdHo2nv7o40dDTI9dO05yHd6Hqv7I7HCD3bsq5UXfQjhDP+zNSdbiVrbF16/5WqNe9zdzSZu3TM7X/zpg/narbXT+XdcLfMxGUdbFf22QwTE/kGFc+xzxOpDoL0nxF9+TElXK0S+Ce/C2n8lVWOvgGyDMZx9a4KEuep+za/8S3v0rW52DgsxLqOQ9oyHPoi89Rx2cu6u+y0h9yvIw1y640Io35oCyaaPvZFlfy0NByR5NjS0hn7DXOOLFJ0phz15O4KRuwCWyPegTbWUEdNE66Nrlmn6hjPjqrsdpD5wes1/383vmIxDVAfa9AWZ7DPW1sreHh1zb4kE2GwIK8BuXSSDAOjKH7ucxnadSUBcobZ7Jd2J7oyceIwDYwPAzbRUGbj4bnVLKvXOnHtXHlSbv2PzGP8eeiIY22gCv3FdKoT1A/N0OgHtq+Et04xfFC1WRLI7TRNpkb5kQHo3PhSjrxOkdH0I0FSFeDGk8b7dYxZW2X8WpvarNaT5Qhv9Ml2wTitU/qbR7rQOfOvNlv/YDzwLXrU+cjEtonnfq0Z//of86zfSct1/BwQd3k25sMIiM2k88kbeEECZPHpBJqXfIoT/vp9JhQ47RVjSX7mMYAlNUZP5qqC2RfuXK/NS41ML/2P9E5UoYxMTbKkUZelqlYhjlj4ZjmYqFNN59XoRunkMeYoGqypZF1Ms6Ve+YnbS/LHEk3FliNh7j2gi3qxBPHDG4c2Jr2VtcU6bRDnvZdyTaBeNe/LJfxzg+4trTpFdlOkm1eWztc6xoeLlTdvr3JiKcMJppyhoS6maZjZbLIq8aK4ZDP6cp6lCOdZ3HN/mBctGkadTJ/tYgeQT5H6J8LOI3W9NW4iKNF7X9ie7nY1bF7ZkJa9g24z03mljfTM9GNU8hT56rJlkY5N8adEw9IkmWOpBsLrMaT8ZUWjhlqGeJpR4lOv8vPNoF416csl3GurheupnO/5fSrj0hyTdT+Ab6INPIoW33TcKHq9rBNRuPzashTBfdOiA6RKxCvGwCnaQJGgcEC5TqjxSlrYJSB2l+cscbxaPI5kn1VF2BMGOe1cd2itxC3fPfMhDRCvq2gG9qg0SsunG6cQp7jqZpsaWSdjKsxoBfzh+2p3dF0Y4HVeDK+0iLHXMsQJ20FNoY2lWwTiHd9ynIZ59o9t/qVpPMRSbaZz2JeWauOnbzONw0XqrYP3WQ6Y0qcILCt3GRq27aZ7RKvm4SbB21lH7v+mvZoh1CfA6RptKkP/fcEJt24uv5LzSPuIvKZPqdCWTYSri4QF5KL8NVY6QTkoRdU3bY0ss6qvnOKs+mc2hHk2JLVeDKeNprUMecziGtvHdpZJdsE4l2fslzGu/Ui2C+2nKx8REKaY8kyjIEApJGnVp1en07V9mGbTDexFScIcIjc5yZTFzt5pOeJ2xNEYluQfVz1l7RHO4XuOejhQkh97G8dl4YsW3qrDYuHQJwNg3bcJGivagWUpW309pn2ifRHa/MMVjqB4wI04t437HQgSdbJOFefRT2cDdpd+3eAZ2HfKqvxENexMp5uDeeYtZO0O9JW0F63iWebQLzrX5bLOHbd2Ta4NhL7DfXZkgcsNLEMV+o4XuKdbxouVG2/tckgOmJzZUcnfwsnCKzDZDphGrs4qXlisQ84C/K5Wp+FzkIhnmWFfAJp1H0k+Ryh3y5aro7PPuS4yEMP+sV4oPa/QnnKsoBcyNQhTjtcOwdAm5SzfXWhPe4Jr7Z4tnRyvIIu6I1GjHlLoxpXM6AN4oZ8xlHYt4oO1P7n2Jhr1hFadG8H6aDRjLh2p80m2q8bel3XkG0C8eyTcfu7iqcfAOyYvLpZrnxEQjo6UYb6llEX+0z76tDp9elUbe/aZKph5GTcIjblaEOIM6ku+g7azzrAs5h4AhMOLBTa50p7GEHtr2VWz/oO+RyhD/YHA07ou4tRNH7L1v5XqK9+2ZbteCqrkKem1KUcmqqbG44L9xXY0inHC+pG+spus07Gc06wTbQCNEezo7FvFZ0y9phryjSvzH+FNPRifK4r7gnVhsH2KL/St7ZJ+Wt6ZxyqH2AubHOrX1wpV8eq3VOGNUEZUDvu0U6f0/mm4dc2eNcmcwSdMaxwwR/B2XS7FxeWsBC7hXpWnq0/2qCR6IiOZqsP3TqivE7zE7jmI9Co06lLu8c3fRLVBk+9yXCS9jRxds6k21fwlAYsnFdbQM/WH9v0FA5s0PVt9Qju1YHyn7TJPIpX8k3PptrgqTcZXofPsHBv4Uy6fQVOeJzMcZwsnlf7GeAI/fnZVb2w0zNsyvfqQPn5yed+Xsk3PZtqg6f/uexVGN2OZfS/MDoMRzObzE6Mbscy+l8YHYajmU1mJ0a3Yxn9L4wOw9HMJrMTo9uxjP4XRofhaGaT2YnR7VhG/wujw3A0N20yEyZMmDBhwldDMm8yD2J0O5bR/8LoMBzN1U1mGIZhGB7FbDLDMAzDTvzyy/8HkoYHRJJnBM4AAAAASUVORK5CYII=" /></p><p>You must not take this medicine for more than 5 days to prevent delayed nausea and vomiting that may occur after chemotherapy.<br />Primperan 10 mg scored tablets is not suitable for use in children weighing less than 30 kg.<br />Other pharmaceutical forms (for example, oral solution) should be used.<br />Frequency of administration<br />You must wait at least 6 hours between each dose, even if vomiting or rejection of the dose occurs, in order to avoid overdose.<br />Elderly patients<br />The dose may need to be reduced, depending on kidney and liver problems and overall health.<br />Other pharmaceutical forms may be more suitable for use in this patient population.<br />Adults with kidney problems<br />Talk to your doctor if you have kidney problems. The dose should be reduced if you have moderate or severe kidney disease.<br />Other pharmaceutical forms may be more suitable for use in this patient population.<br />Adults with liver problems<br />Talk to your doctor if you have liver problems. The dose should be reduced if you have severe liver disease.<br />Other pharmaceutical forms may be more suitable for use in this patient population.<br />Children and adolescents<br />Primperan 10 mg scored tablets must not be used in children under 1 year of age (see Section 2).<br />If you take more Primperan than you should<br />Contact your doctor or pharmacist immediately. You may experience abnormal movements (extrapyramidal disorders), drowsiness, consciousness disorders, confusion, hallucinations and heart problems. Your doctor may prescribe treatment for these symptoms if necessary.<br />If you forget to take Primperan<br />Do not take a double dose to make up for a forgotten dose. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Primperan can cause side effects, although not everybody gets them.<br />Stop the treatment and contact your doctor or pharmacist immediately if you experience any of the following symptoms while taking this medicine:<br />- Abnormal movements (often involving the head or neck). These may occur in children or young adults, particularly when high doses are used. These symptoms generally occur at the start of treatment, and may even occur after administration of a single dose. These movements will stop when treated appropriately.<br />- High fever, high blood pressure, seizures, sweating, excessive saliva production. These symptoms may be signs of an illness known as neuroleptic malignant syndrome.<br />- Itching or skin rash, swelling of the face, lips or throat, difficulty breathing, which may be signs of an allergic reaction which may be severe.<br />►Very common (affecting more than 1 in 10 patients)<br />&minus; feeling drowsy.<br />►Common (affecting up to 1 in 10 patients)<br />&minus; depression with mild to severe symptoms including suicidal thoughts.<br />&minus; abnormal movements such as tics, shaking, twisting movements or muscle contraction (stiffness, rigidity)<br />&minus; symptoms similar to Parkinson&rsquo;s disease (rigidity, tremor)<br />&minus; nervousness<br />&minus; blood pressure decrease (particularly with the intravenous route)<br />&minus; diarrhea<br />&minus; feeling weak.<br />►Uncommon (affecting up to 1 in 100 patients)<br />&minus; raised blood levels of a hormone called prolactin which may cause milk production in men and women who are not breast-feeding<br />&minus; irregular menstrual periods<br />&minus; hallucinations<br />&minus; consciousness disorders<br />&minus; slow heart beat (particularly with the intravenous route)<br />&minus; allergy<br />►Rare (affecting up to 1 in 1 000 patients)<br />&minus; confusional state<br />&minus; seizures (particularly in epileptic patients).<br />►Frequency not known (cannot be estimated from the available data)<br />&minus; abnormal blood pigment levels which may change the color of your skin<br />&minus; abnormal development of breasts (gynecomastia)<br />&minus; involuntary muscle spasms after long-term use, particularly in elderly patients<br />&minus; high fever, high blood pressure, seizures, sweating, excessive saliva production. These symptoms may be signs of an illness known as neuroleptic malignant syndrome.<br />&minus; changes in heart rate, which may be seen on an ECG<br />&minus; cardiac arrest (particularly when administered by injection)<br />&minus; shock (severe decrease of heart pressure) (particularly when administered by injection)<br />&minus; fainting (particularly with the intravenous route)<br />&minus; allergic reaction which may be severe (particularly with the intravenous route)<br />&minus; very high blood pressure.<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />- The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2340.<br />o reporting hotline : 19999<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br />&bull; Sanofi- Pharmacovigilance: KSA_Pharmacovigilance@sanofi.com</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>KEEP THIS MEDICINE OUT OF THE SIGHT AND REACH OF CHILDREN<br />Do not use Primperan after the expiry date which is stated on the box. The expiry date refers to the last day of that month.<br />Store below 30&deg; C.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Primperan 10 mg scored tablets contains<br />The active substance is:<br />Metoclopramide hydrochloride...................................................................................10.50 mg<br />Amount equivalent to anhydrous metoclopramide hydrochloride ...............................10.00 mg<br />for one scored tablet.<br />The other ingredients are:<br />Lactose monohydrate, microcrystalline cellulose, corn starch, anhydrous colloidal silica, magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This medicine is supplied as scored tablets.
Box of 20, 40 or 150.
Not all pack sizes may be marketed in your country.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder<br />sanofi-aventis France<br />82, avenue Raspail<br />94250 Gentilly,<br />France<br />Manufacturer<br />Delpharm Dijon<br />6, boulevard de l&rsquo;Europe<br />21800 Quetigny<br />France<br />Secondary packaging<br />Sanofi Aventis Arabia Co, Ltd.<br />Industrial Valley Phase 1A St. KAEC,, King Abdullah Industrial Valley Phase 1A St. KAEC,, Abdullah Economic City, Rabigh, 21423, Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                10/2016
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>بريمبيران هو مضاد للقيء. يحتوي على مادة دوائيّة تُسمّى &quot;ميتوكلوبراميد&quot;. يعمل على قسم من الدماغ ليمنع الغثيان والتقيّؤ.</p><p>&nbsp;</p><p><u>البالغون</u></p><p>يُستعمل بريمبيران لدى البالغين:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لمنع الغثيان والتقيّؤ اللذين قد يحصلان بعد المعالجة الكيميائيّة،</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لمنع الغثيان والتقيّؤ اللذين يسبّبهما العلاج الإشعاعي،</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج الغثيان والتقيّؤ، بما في ذلك الغثيان والتقيّؤ اللذين قد يحصلان مع الصداع النصفي.</p><p>&nbsp;</p><p>في حالة الصداع النصفي، يمكن أن يُؤخذ بريمبيران مع مسكّنات فمويّة لمساعدة هذه المسكّنات على العمل بفعاليّة أكبر.</p><p><u>الأطفال</u></p><p>يوصف بريمبيران لدى الأطفال (من عمر السنة وحتّى عمر 18 سنة) إذا لم ينجح علاج آخر أو لا يمكن استعمال علاج آخر لمنع الغثيان والتقيّؤ اللذين قد يحصلان بعد المعالجة الكيميائيّة. ليس قرص بريمبيران 10 ملغ مناسبًا للاستعمال لدى الأطفال الذين يقلّ وزنهم عن 30 كلغ. يجب استعمال أشكال صيدلانيّة أخرى (المحلول الفموي مثلاً).&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>إذا أعلمك طبيبك أنّك تعاني من عدم تحمّل بعض أنواع السكّر، اتصل به قبل أخذ هذا الدواء.</p><p><strong><u>موانع الاستعمال:</u></strong></p><p><strong>لا تأخذ بريمبيران إذا:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من حساسيّة ضدّ الميتوكلوبراميد أو ضدّ أيّ مكونّات أخرى في هذا الدواء (مذكورة في القسم 6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من نزف أو انسداد أو تمزّق في المعدة أو الأمعاء.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني أو قد تكون تعاني من ورم نادر في الغدّة الكظريّة التي تقع قرب الكلية (ورم القواتم).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عانيت يومًا من تشنّجات عضليّة غير إراديّة (خلل الحركة المتأخّر) عندما عولجت بهذا الدواء.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من الصرع.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من داء باركنسون.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تأخذ الليفودوبا (دواء يُستعمل لداء باركنسون) أو مضادات الدوبامين (راجع فقرة &quot;أخذ أو استعمال أدوية أخرى&quot;).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك مستويات غير طبيعيّة من صباغ في الدم (ميتهيموغلوبينية الدم) في دمك، أو كنت تعاني من نقص في سيتوكروم NADH ب5،</p><p>لا تعطِ أقراص بريمبيران 10 ملغ للأطفال ما دون السنة من العمر (راجع فقرة &quot;الأطفال والمراهقون&quot; أدناه).</p><p>يجب استعمال أشكال صيدلانيّة أخرى (المحلول الفموي مثلاً) لدى الأطفال الذين يقلّ وزنهم عن 30 كلغ.</p><p>لا تأخذ أقراص بريمبيران 10 ملغ في الحالات الموصوفة أعلاه.</p><p>إذا لم تكن متأكّدًا، تحدّث إلى الطبيب أو الصيدلي قبل أخذ <strong>بريمبيران. </strong>&nbsp;</p><p><strong><u>احتياطات مناسبة للاستعمال؛ تحذيرات خاصة:</u></strong></p><p><strong>استشر الطبيب أو الصيدلي قبل أخذ بريمبيران إذا:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أصبت في السابق بضربات قلب غير طبيعيّة (إطالة فارق كيو تي) أو بأيّ مشاكل أخرى في القلب،</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك مستويات غير طبيعيّة من الأملاح المعدنيّة، مثل البوتاسيوم والصوديوم والمغنيزيوم في دمك،</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تأخذ أدوية أخرى يُعرف أنّها تؤثّر على ضربات القلب لديك،</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من اضطراب عصبيّ (في الدماغ)،</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من مشاكل في الكبد أو الكليتين. قد يتمّ تخفيض الجرعة في هذه الحالات (راجع القسم 3).</p><p>قد يصف لك طبيبك فحوصات دم للتحقق من مستويات صباغ الدم لديك. إذا تمّت ملاحظة مستويات غير طبيعيّة (ميتهيموغلوبينية الدم)، سوف يتمّ إيقاف العلاج على الفور وبشكل دائم.</p><p>يجب أن تنتظر 6 ساعات على الأقلّ بين كلّ جرعة، حتّى في حال حصول تقيّؤ أو رفض الجرعة لتفادي فرط الجرعة.</p><p>لا ينبغي أن يدوم العلاج لأكثر من 3 أشهر بسبب خطر حصول تشنّجات عضليّة لاإراديّة.</p><p><strong>الأطفال والمراهقون</strong></p><p>قد تحصل حركات غير طبيعيّة (اضطرابات خراج الهرميّة) لدى الأطفال والشباب. لا ينبغي استعمال هذا الدواء لدى الأطفال ما دون السنة من العمر بسبب زيادة خطر حصول حركات غير طبيعيّة (راجع فقرة &quot;لا تأخذ بريمبيران إذا&quot;).</p><p>ليس بريمبيران مناسبًا للاستعمال لدى الأطفال الذين يقلّ وزنهم عن 30 كلغ. يجب استعمال أشكال صيدلانيّة أخرى (المحلول الفموي مثلاً).&nbsp;</p><p>لا يوصى باستعمال هذا الدواء لدى المرضى الذين يعانون من عدم تحمّل الغلاكتوز أو من نقص لاكتاز لاب أو من متلازمة سوء امتصاص الغلوكوز &ndash; الغالاكتوز (أمراض وراثيّة نادرة).</p><p><strong><u>أخذ أو استعمال أدوية أخرى</u></strong></p><p>أعلم الطبيب أو الصيدلي إذا كنت تأخذ حاليًا أو أخذت مؤخّرًا أو قد تكون تأخذ أيّ أدوية أخرى.</p><p>هذا لأنّ بريمبيران قد يؤثّر على طريقة عمل بعض الأدوية. كما أن بعض الأدوية قد تؤثّر على استعمال بريمبيران.</p><p>تتضمّن هذه الأدوية ما يلي:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الليفودوبا أو أدوية أخرى تُستعمل لداء باركنسون (راجع فقرة &quot;لا تأخذ بريمبيران إذا&quot;)،</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الكولين (أدوية تُستعمل لتخفيف تقلّصات أو تشنّجات المعدة)،</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشتقّات المورفين (أدوية تُستعمل لعلاج الألم الحاد)،</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المهدّئة،</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستعملة لعلاج مشاكل الصحّة العقليّة،</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الديجوكسين (دواء يُستعمل لعلاج فشل القلب)،</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السيكلوسبورين (دواء يُستعمل لعلاج بعض مشاكل جهاز المناعة)،</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الميفاكوريوم والسوكزاميثونيوم (دواءان يُستعملان خلال التخدير لاسترخاء العضلات)،</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفليوكسيتين والباروكسيتين (دواءان يُستعملان لعلاج الاكتئاب).</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>الطعام والشراب</strong></p><p>لا ينبغي استهلاك الكحول في خلال مدّة العلاج لأنّه يمكن أن يزيد التأثير المهدّئ لبريمبيران.&nbsp;</p><p><strong>الحمل والإرضاع</strong></p><p>إذا كنت حاملاً أو تعتقدين نفسك حاملاً أو كنت تنوين الإنجاب، استشيري الطبيب أو الصيدلي قبل أخذ هذا الدواء. عند الضرورة، يمكن استعمال بريمبيران خلال الحمل. سوف يقرّر طبيبك ما إذا كان عليك أخذ هذا الدواء.</p><p>لا يوصى باستعمال بريمبيران إذا كنتِ مرضعة لأنّ الميتوكلوبراميد ينتقل إلى حليب الثدي وقد يؤثّر على طفلك.</p><p><strong>قيادة السيّارات واستعمال الآلات</strong></p><p>قد تشعر بالنعاس أو بالدواء أو قد تُصاب بحركات تشنّجيّة غير طبيعيّة وتشنّجات معممة تشوّه الجسم بعد أخذ بريمبيران، مما قد يؤثّر على بصرك وعلى قدرتك على القيادة أو استعمال الآلات.</p><p><strong>تحتوي أقراص بريمبيران 10 ملغ القابلة للتجزئة على اللاكتوز.&nbsp; </strong>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>خذ هذا الدواء دائمًا حسب تعليمات الطبيب أو الصيدلي تمامًا. إسأل الطبيب أو الصيدلي إذا لم تكن متأكّدًا.</p><p>&nbsp;</p><p><strong>مقدار الجرعة</strong></p><p><u>دواعي الاستعمال كافة (المرضى البالغون)</u></p><p>&nbsp;</p><p>الجرعة الموصى بها هي 10 ملغ، تؤخذ حتّى 3 مرّات في اليوم. تبلغ الجرعة اليوميّة القصوى 30 ملغ أو 0.5 ملغ/كلغ.</p><p>مدّة العلاج القصوى الموصى بها هي 5 أيّام.</p><p>&nbsp;</p><p><u>الوقاية من الغثيان والتقيّؤ المتأخّرين اللذين قد يحصلان بعد المعالجة الكيميائية (الأطفال ما بين عمر السنة و18 سنة)</u></p><p>تبلغ الجرعة الموصى بها 0.1 حتّى 0.15 ملغ/كلغ، لغاية 3 مرّات في اليوم، تُؤخذ عن طريق الفم.</p><p>تبلغ الجرعة اليوميّة القصوى 0.5 ملغ/كلغ.</p><p>&nbsp;</p><p><u>جدول مقدار الجرعة</u></p><p><img alt="" width="507" height="152" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZkAAACpCAYAAAD5qEDXAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAADsMAAA7DAcdvqGQAAC0wSURBVHhe7Z1NrizNVp49FFsMApiB8QhsTwAkunbDPbvhJkKiCRJdu+H2FX0QA7hiACDaIGbwWc+t8+i8Wt+KrKq9KyuzqtYjhTIy/jLijRUrIuvo5P53vwzDMAzDTswmMwzDMOzGbDLDMAzDbvxqk/m9f/8ffsSGexjdjmX0vzA6DEdTbbDdZCZMmDBhwoSvhmTeZB7E6HYso/+F0WE4mtlkdmJ0O5bR/8LoMBzNbDI7Mbody+h/YXQYjmY2mZ14Bd1+85u/+eUv/+qvf9y9F2O3F0aH4Wi+tcn8xz/6T7/88Z/86Y+7Iel0Qy/SCcT/5//63z9ybsN6j+I//5f/+rs2//Gf/vlHyq+xz6/GtT6zwVLGgB3/y7/+24/c9+GWuata/Nmf/8WPnGH4PtUG79pk/uD3//ChTu+d6HTTYePUdfD3vElQ/pF6/5//+/+ubnSrTebsm8+1vulYGQfzQfy//ff/8SP3fbhljlKLYXg01QZv3mR++9t/+F0eYesk/Kl0uqVjxrkTv+fUSPlHO4Jrp/fVZrJKPwvX+lYd69nH81VuGdNsMsOeVBu8eZPhFEweASMVfnbAWA1/+3d//ztHZvq9PxG9Kp1ujN90Ts3EfZPpNCLNNx7yuJJvnM2d+qTZHpBPGx4EoGs/+wPmG5g7y3jleWyMxE0/IzmujtUmoy2vbFadPRyc3bav6QCrTYY0xssvFpTpxoqNkU/QFoGrz844UBe7JlAfbNO28C/AM9WcZ3NNux/OT8493LzJsMgwBvJdcEw89zo3DVFDNT03pXel0y0Xm4uMRQRoRL4aoaV6ck1HYDppaIz+On42BtqlHPnEbb/OQfZnNXeWIZ22aCPTz8q1vqWe4HhIh635wMnlvJ3ZtunTNaoWQhpjwxZ09nWsOH7T0iZW8bRd2qM+kJZ6m86zuceuO7sfzg9zlty8yWAQGEkahI4OuFIGdHpA+icYR6ebi01tWDTCfWqEtuor1tMpoCP3nPpM8w2ThU/7tAHdHHBPHFZzl2VW8TNyrW/qVcdJuvfmkY6OOjlP2XB226ZP11ALg2Mg7thgZUOmcSV9K+6mASubyzhX453dD+fHOZabNxmdWBqE98A1TymUpxzxsy3EPVCHxPGDG4gbDXF1NJ7loZbJU6T/eE0+zoB4nva4r3OQ7a/mLsus4mfkWt+ubTKZZxyN0ZBA3Lwz2zZ9ukbVQmpaN9YsY/otca6ZbtpWHLhPux/Oj3MsN20yvtL600yW8bTD1Z8UyE9D+QQ63dDA9LpAu3iWhyxjvvegA7BtQuc0hftsv5u7LLOKn5FrfVttMjquzMu4m7FviJl3RujfNe7ZZLbKcPV5t8STbGcVB+KG4TWo833TJqNRZtCZ4aAqOq9PotMNDUzvToHGSecthBNbtpPlre8bB9g+c2HcE3c3B5aRbu6yzCp+Rq71rTpWxs4mLaSbRznmQ/JnzLPb9i1zdOsm043Vgw1w9XmruD+XaZeSz8o417TLzu6Hc+Pcy02bDBPtxHuy82cfjE4joRxoWLz5uBm9O51uudjQL3XDcZHvWyLpLig0899aXHzeWx8sD/6kIN0cZH+gm7sss4qfkWt9S8eq5o4Zuvng7c5/ACcPzm7b13SA1CKpad1Y86cr7cd04qTThuk+Sz1pC0jzWRl3Q6cc5Tu7H84N85XctMlgQEw+aDTec8UYNTiNSafKlft3p9PNxUYgnk6Nk5356GeaOqKb2ppHejo2tHZx0rZx6ObA50k3d1km4yx2ytHWGclxdWi3Bu1XuvlwzKTjPOHstk2/rqEWjCupad1Y3Vwop17gZkAe+mU72CbpBDeLfFbG85nU6+x+ODfMV3LzP/x3YDAYBGAQGsYnco9uX+WRz3i3uXuG/q/AM3XITWZPZm5fizpf39pkcEqeQDi9UNfX4U9j74XASdFN4RG829ztrf+r8EwdnrHJPNruh/2pNvGtTYZXW35KwwgIGMSnsvdiy5/OHsG7zd0zneuZeaYOz9hkHm33w/5Um/jWJjP8ZHQ7ltH/wugwHM1sMjsxuh3L6H9hdBiOZjaZnRjdjmX0vzA6DEczm8xOjG7HMvpfGB2Go5lNZidGt2MZ/S+MDsPRzCazE6PbsYz+F0aH4Whmk9mJ0e1YRv8Lo8NwNLPJ7MTodiyj/4XRYTia2WR2YnQ7ltH/wugwHM1sMjsxuh3L6H9hdBiOZjaZnRjdjmX0vzA6DEczm8xOjG7HMvpfGB2Go5lNZidGt2MZ/S+MDsPRzCazE6PbsYz+F0aH4Whu2mQmTJgwYcKEr4Zk3mQexOh2LKP/hdFhOJrZZHZidDuW0f/C6DAczWwyOzG6Hcvof2F0GI5mNpmdOJNu9OU3v/mbH3efwdjthVfVgT+z/I//9M8/7o6H9TM29TWqbndtMn/5V3+9mc/f4v6D3//D34Vxchd++9t/+JUeLCb+rj5/I/3a3y/f0pz6nc6Uf/W/2X8v9+j/zmytz2eRfuCWv8//L//6b6ezWfpyBi1fkarbzZsMJw2MZkt4FjSwoHGAn0SnizqQlwuIDYbNA8hfLa4tzf/27/7+V+3KKv2duUf/d6bT4bug4z3tph+gHtdKbRN7PhPYyx5afgJVt5s2GQT/sz//i7uEpxwnlE+h6sLY//hP/vR3by3k6eRYgNz70wAbCeUq1zSnTrabrNLfmarRSv8VlE97fVXb7WzlFur4k5UN3gL1ureZW9o8ck6+M+ZPp+p2189l9whPuWoUGJtvOOTZFqcYfz7SGeQpNI2UexwzVxwIjpi4bwZH4Vg6yMtxZVn6ryYdneaMe+uEnuno6kkSjXC8/pTxzEW7N1WjZKUToKM2ZDk0yzrohG6md4eCs0D/OkjXDjLO+FlfpGETHn7EQ5EBLViv1CPYzgrqoG/Stck1+3RtTkB/Qp793vIHlNf2u347z9T3CpTlOdzThs8F+z78pOqxyybDpHQL0foaKsZB3EnX+EgjztWTqK/TxKnHvXlcKXsk9GMFeS6O+m8s9b7Sac5Csl4uOjGd4DygD+lcqctCeSe2NFzpBOTppNDEsmisI0FDN2Xysc2zstIhNahxxg9cOcBVKGu7aOB6ZQ2Svlp7lCG/0yvbBOK1T1tzgg3bb8owR9f8gT6EuoyhQvukUz83meqL7Dtp+rHhJ+omD91kEN0dHwOruIkwMTo6DVGjMD8hLQ2QumB7TP7R0I8V2X/6nmXrfaXTHI3RK9tNSKddyqkNmrqwqNMdAl6ZLQ1XOkHmpdYZ56peW22dAftcyX7XuOuJ9agTT1KLXK/aYF3r6QdosyPbBOJd/7JcxnHstk06tn2rP8h2kmxztS5JMy/92PCTqtuXNxkmlHtDQp4nggrpnBg4MVHPCcMoNcw0WsqS5jMyDtQ5wySrS0f2uRqv9ys9iWd5tPG0me0mpKMzbYtzAtTpTqyvTGpUWekEmZdaZxzdPK1utXUG7HMl+72KV9uU1KKWIZ52luj0u/xsE4h3fcpyGefKvLD+uZp+zR/gk5hLyye5Zmr/IH0RZdOPDT+pun15k9HYDHVD4eTXiU86gYnGCKvRCqchyphvWxkHThOk1befZ9ONQbLPdbzer/RMzQHtHCvpnca24elbWBi0+44LIzWqrHSCzEutM47TQjudZnd4Ogv2uZLjXMVXazG1qGWIk7YCG0S7SrYJxLs+ZbmMc+2eu+UPOKC5CdlOkm3mszpfVP3Y8JOq7W7/8I8j64yANIxOw7NNJjKhvqdtJ7bGBaNhso9kS5fsc9WQ0xCGv6KWJ15D1Y40tOOaCwDtz/Lm92gY6wryqs1I5qXWGdfJoF39aehsrHTIca7irs1KaqGjFeLdOhftsJJtAvGuT1ku4/STtdPR+QPmkDpsPvXZQppjyTKdL1KrTq9Pp2q72ybDJHcL0pOGp2zv62mANJ6HcRjP9MQ2jmTr+dnnehpOA+7Y0jzbTUzHKWbbxFkc3Snv1VlpBCudIPNS64xjx5Y781sM2OdKjrPGdazYR3dY67RgXbo2tzZeN+dKtgnEu/5luYz7JtHR+QP7DfXZkgcwNLEMV+qkL6p+bPhJ1fahm4zOC0fKDs+kVJyoPIXk5NqGJ5Vc4JBxYNFz3y2OZ7KlS+0z48WI0YJxbi3SLc1ru2K6dXWMLhzCuy0OxrRCPToyT71qHP2YJ+632joD9rniGnNcjoE4tuCa7d4O0kG7flmnpHfrPP0AZd3EkmwTiGefjNvfVZxn8HyusPIHbgrks5naTkI6OlGG+pbpfFHnx4YLVdu7NplqGBWMlXwmSkPrYAJpSzAQ6lDXk7dGRDrluQfSrIsxkI8RbD3vGWzpkn0G+up4rxnplua1Xcl0nuMGjo5oRkAzF+Y7sNIIVjpB5qXWGWeOdFpoiXZnZaWD64k1muvPNK91wwDSXGfEqcs9oVt3tqdz7qhtUj77ZDznIeNA29QnML5r/iDHSbk6VtcFZZhnysDKF6WOw09yjuCuTeZRdBPccUuZs/AM3b4Di47FJcSP3pgfyZ7607YbtQ7nrGz1rVtPlNdpfgJsJFugUadTl3arH/s0qg0+fZPxreXdOLPjAXT31Eh4twWyp/6eYIHNxrftM3KvDpT/pE3mUbyrH3sE1QafvsnwinvmRfpV9tbtEfjzAovj3V7z99Sf0y9vfmjH9cyb8706UH5+8rmfd/Vjj6Da4CE/l70jo9uxjP4XRofhaGaT2YnR7VhG/wujw3A0s8nsxOh2LKP/hdFhOJrZZHZidDuW0f/C6DAczWwyOzG6Hcvof2F0GI7mpk1mwoQJEyZM+GpI5k3mQYxuxzL6XxgdhqOZTWYnRrdjGf0vjA7D0cwmsxOj27GM/hdGh+FoZpPZidHtWEb/C6PDcDSzyezEmXSjL5/2qZCx2wuvqgOfaLn28cpnUr/4PNxO1e2mTYbJ5wOB5HFdGQP5Gbq/I/GuMN4OP0yZTr/qtEX+8STgu1ksSL4/xrX7jhblP+2jh52O6EM6+n+KLV6zp2fgn0Mg+PXqLbDhs9ns2b+2fWaqbje/yfi3R/hAYH4yPtFQDNb5BDrd2FjYDNRFUqetNw6cJAs128ZZqj8bfuc86/M+gU5//5QBWpD/Tn/aYEWnw3e591TvurdeZ+O1zbPNjTYz3E/V7e6fy7bE/+RJqWPndMZmwFsfeen0b9GJ8nzpteqdGwv5foI+qc/7BK5pSv7W2wzzlW+F3RviK3CLbXXU8Sdba/4a1OveZm5p88g5+c6YP52q25c2GU7XHdfqYmz+DQYMxvKcYnCW5OkcOen4FpBGyr0/g+DAcbTEj/45xLF0kOe4YKtspRp7tsWYu7nIMujqSZLybHz+lPHMRbs31zQlv7MRbEwbUjc0Sw3RCd1MX73JnwH610G6dpBxxs/6Ig2bqD+F81ZCngEtWK/UI9jOCuqgb9K1yTX7dG1OQH9Cnv3e8geU1/a7fjvP1PcKlOU53NOGzwX7Pvyk6nH3JoP4iNxBXSexK4OBUEZDxTiIO+kaH2nEufom4Os0cepxbx5Xyh4J/VhBXi4O7hkzhuq4VqiZZFsspO65liHoENGHdK7UW83hq9LpIGhMvj/jJKTrpNBE7XBWOhI0ZL7UsGvnLKx0cFxdnPEDVw5wFcraLhq4XtV1tfYoQ36nV7YJxGuftuYEG7bflGGOrvkD1xp1GUOF9kmnfm4y1RfZd9Jo034MF9RNbt5kEJYJcBI6nEQmhXJMWkI67VNOR6chahTmJ6SlAVIXbG/Vn2dCP1Zk/8HxadSrRQoatLDIHL8LsEIaZSirNjyTZwFtuvm8C1v664Q6cm5S64xztX6WPyP2uZL9rvG0J514klrkeiUQJy0hnXbIo82ObBOId/3LchnHsds26dj2rf4g20myTTTpypBmXvqx4SdVt7vfZDxNMKFMlqGyMlg3H05M1HPCKKthptFSljSfkXGgzhkmeUu32mfJRbrSk3i2zVhxeLmQK6Shs84DaD83me7E+sp0OoAa14OLkKfeqXXG0c3TapY/I/a5kv1exVeONbWoZYinnSU6/S4/2wTiXZ+yXMa5Mi+sAa6mX/MHbEDMpeWTXDO1f5C+iLLpx4afVN3u3mSYJMpobIZ6eqjGKDhIAhONEa7K4RwoY74TmXHAeZC2ciLPohuD1D4n5DHGlZ7U417UBSNHR64V2/D0LZSl3XdcGKlRgiOoOiTUU4vUOuM4LbTTaVZbPxMrHXKcq/hqLaYWtQxx0lasbDTbBOJdn7Jcxrl2z93yBxzm3IRsJ8k281mdL2JcBP3Y8JOq7d2bjCdDjWAFE9IZl+nmOZm0m+AIPW3n87pnYzRM9pFs6balF3ndYhH16cCBduOmPNpxzQXAc87y5vdoOo2wKexsa1OgnnOTWmdcJ4N29aehs9HpADnOVXy1ZlMLyuQziG/Zr3ZYyTaBeNenLJdx+on9d3T+QFtg86nPFtIcS5bpfJFadXp9OlXbL7/JXHtzcJeveNLwdOl9PQ2QxmTWTS3jYhtHsvX8rs/gyXhLS+qt2kbDbqH5PJyiiwOIsziuzd0r0mmEs1k5Ism5Sa0zzsZiuTO/xUCnA+Q4a1zHin10a7bTgnXp2tzaeN2cK9kmEO/6l+Uy7ptER+cP7DfUZ0sewNDEMlypk77IZ6z68MlUbW/aZFhYLi4WbWc0TIDOywnojM+JysWfk2sbnlRygUPGgX5x3y2OZ9LpJtnn1Ikxd1om1Mu2qQ9q3Dk9n2ddy7hwCO+2OBhTwphTB0L3s4ZlQL1qnLawR+6z/BmxzxXXmONyDMSxBbRxzVXSQbt+sT/SqaNNivbtIcpNLMk2gXj2ybj9XcV5Bs93blf+INcLm6ntJKSjE2Wob5nOF6lDp9enU7W9aZNhghCfPMRnEio5MZTtDEsox4QJBmL7nrw1ItIpzz2QZl2eST5GoGEfBf1aUfusTistk7oYU5fUMMnnUc4N3OcR0MyF+Q6kRpAbqkEdEtLVKrXOOI4E7YA20O6s2OeKdsOGwlgcs2le64YBpLnOiFOXe0K37mxP59xR26R89sl4zkPGgbapT2B81/xBjpNydayuC8rkAXDli1LH4Sc5R3D3z2WPoJvgjlvKnIVn6PYdWHQsLiF+9Mb8SPbUn7bdoHQ4Z2Wrb916orxO8xO4dqhDo06nLu1WP/ZpVBt8+ibjW8u7cWbHA+juqZHwbgtkT/09wQKbjW/bZ+ReHSj/SZvMo3hXP/YIqg0+fZPhFffMi/Sr7K3bI/DnBRbHu73m76k/p1/e/NCO65k353t1oPz85HM/7+rHHkG1wUN+LntHRrdjGf0vjA7D0cwmsxOj27GM/hdGh+FoZpPZidHtWEb/C6PDcDSzyezE6HYso/+F0WE4mtlkdmJ0O5bR/8LoMBzNTZvMhAkTJkyY8NWQzJvMgxjdjmX0vzA6DEczm8xOjG7HMvpfGB2Go5lNZidGt2MZ/S+MDsPRzCazE2fSrX5I8BMYu73wqjrwv+evfVfsmXziGnoUVbebNxnSM6zgo4t85+kdP12yRacJC4d0PkeSX6VGI/QhbH2kcqv+lsZn/4jjHtyjf0J+hlfnDGPwS9UEPyy6BZ/pod9n+obaJ66hR1F1u2uTQXjC1uah48MRYmTv9BHGLTrd3EA0WO/ViIBGK67VX2n8iQvkHv0T0sknbNn1q7DHvKPLPe36JySs1+la2+zm5kg+cQ09iqrbXZvMNTAuyuH0PJ2czXj24po+5HOaViN+GiDcqlGtv6XxbDK/Rv0q9+iUP+fUjf0sfHXetaeO79gT9bq3mVvarH16puazyXydqttDN5l6OiHOZAnGxikcMJgsax4/A7mY87Xb0xBXyvE1XAL35BM/kmv6kI+Tq8ZbNVph/WsaQz7DT5KjN/X9mnD3BvTKpCYd6le5Vg+9tTXKcqUd43IWbVfjId01lHFsg3VGGv2u/y7iocbAuDjUUI9gOyuoU/9wWdcm1+wTdczHnvELxqXzGdbr5rrzJwn9yHnmCpTlOdzThs8F+z78pOpx1ybD5CDu6uSdzg2I52Sbr6FiHEAZ40ygi9fnkM+zwTYwJh0oRkCbR5LjrjAO8ukvY8myxLsFkWT9axpDlkFX9SGNK+XR+Z1ITSqpX4X0LbtWSzSzHezTONczaUs/OkhnLF3ctce1+3x92hNj1EmrAWkdlCG/0z3bBOK1T2wcaGkea17njs7VZ1Cesly7Pjm/1NWfJLRPOvVzk6H/tGf79p002rQfwwV1k5s3GSfIiVhNouITiDOhwmSRRrlcjEyScSawGkAaZE4waPBHY/86XATAuLMs8dSoI+tf0xjUiKtOg3rqSrrtvQupaSX1q1yz67Q9UNeMn0nblQ5dv41rP+ikE08oa7tuHGl/df2RTjvkua4r2SYQ7/qX5TLe+Qz9C5vBFtlOkm3WdSqkmVf92HCh6nbzJiPp2Jgsg3k6fSdSAxbyWdA4P+tRjnQMk2v2AYNh8k2zXVktjGeTfUrUS2dWjZd4p6XU+rdobDrlXHAsQO6B/O7E+sqkpknVb4XlqsNUSyHuHBk/k7bZ16Trd41X2xTyTV/Zb4dOv8vPNoF416csl3GuaF59BvdbTr/6k4R27GvtH+C3SCOPstWPDReqbndvMkAZjc2gM2ORMgGc5kivE0A6gYnGCMH2KrSl0VAG6uTrdJnwI8k+JfQrT7bqJo6dqyFPYrU+XNNYjWoedWj7HRcGY+3o9FtBG9UOq72lphk/i7YrHVb9zni1TSHf9JX9rkB7tKlkm0C861OWyzjX7rkcJsjrDhWdP0myzXwWPgZ/5djJY1yE9GPDharttzaZa1CuTjb1MLo0POJ1k3DzoP7K0MQ06hxF7RM4htw0av+J19OzdPUr1K8a+wwcHotA0P7aSe9VuVX/LWij2nU3X6TV+Fm07XSAVb/rGNCrQr7tUiafQbxqlmCDWV6yTSDe9SnLZZx+rg6WzEHaPaz8SUKaY8kyjIEApJGnVp1en07V9u5Nxlfg7qSQkE+56vhNz9Olp4IEx2tfVoaWkHatT3vS9QljrwvB8eP4CMRXJ6GufrLSWI2cKzcxFgqL40id9oJxVq7pl6zsutobcdJq/CzadjrAqt/EdayMoTpnSA1cl9gcgfjqkAS0x+ZbyTaBeNe/LJfxzmeI6yJZ+ZMkDwloYhmu1HG8xH3Gqg+fTNX2pk0GcV08TEJnNKLDy90/caJy8TvpLHTyuTqJOGLasV/VQNJZ++wjyD6BfaK/BjcTTj/cY8grLbfqX9OYsvYnF6MLh/Bui8Pxyko/tGPs5BO/ZtepJdhmjZ9F2+xrogN1PDkG+os2q7eDdNBoRhzdSKdOXXdqSpuUdRNLsk0g3ulqf1dx59S1wbySVzfLlT9JSEcnylDfMupin2lfHW49xHwSVdubNpkUnSv3KzBYynGtxie0wYQlTBaTqQOGbIvJp71qnJbpDPmZZJ8gnY7BUxIGzzgZkwuyslX/msapkYuLRejcEXi+C/MdcLyy0g+90E0drtl15wy13YyfRdvsa6JTZuy5/kzz2tkTadgq43INcr+yX9uj/MoJ1zYp3+nKlfsah+oz0N42t/rFlXJ1rM4dZfLQoXbco53+KXUcfpJzBF/6N5nv0k3wim7hn5Fn6PYdWHQsLiG+2uBekSP1P5O2Wzp0a47yOs1P4Jo/QaNOpy7tHj/2SVQbfPomwwnPE8I7caSTuwV099RIeLcFcqT+Z9L2Xh0o/0mbzKN4Vz/2CKoNPn2T4RW3+3eEV+dIJ3cr/rzA4ni31/yj9T+LtvfqQPn5yed+3tWPPYJqg4f8XPaOjG7HMvpfGB2Go5lNZidGt2MZ/S+MDsPRzCazE6PbsYz+F0aH4Whmk9mJ0e1YRv8Lo8NwNLPJ7MTodiyj/4XRYTia2WR2YnQ7ltH/wugwHM1Nm8yECRMmTJjw1ZDMm8yDGN2OZfS/MDoMRzObzE6Mbscy+l8YHYajmU1mJ0a3Yxn9L4wOw9HMJrMTZ9Ktfq32Exi7vfCqOvCJljN9DPcT19CjqLrdvMnwVVk+bX3Lt5n8zLrwsUD/VoOfRH83Ot34XDjfsyKkZmiJFoRrX+ulHuVoww8ZXqvvp8k/iW68pGU4+s9BPINOh2eTdu+fp9gC/0C/z/Shzk9cQ4+i6nbzJoNDw+Hh1DCe1Vdm2UzIz3b4mJyfQsfo8rPo70Knm39TxI1C1JKAVivYjGnXjUTNr9WfTeYCaWhhcD7emT3mHTu7p920e+pxrdQ2rx22ns1sMl+n6nbTJoPRkI6T89SxOkGzodQJYlMhHd518q6NSf3Ukg2kbiKV3JzllvqfuEC68d6jgbYtGX8lvjrvdfzJd+yJet3bzC1tHjknn7iGHkXV7aZNpp46iDMJK+oE4Sj9qYK8evrGCD3pY0jWxXn6E53Py1dxT0hcKcNzCNTjnnae9RNJjreDfMZWtSG+0pKxuznLLfWzDJsSWvBstEAf9Xvmot2b1ES6tAraoDFl1RLdjQM6oZvpxM/Kasyku14yzvhZU6RhExxcEg81BrRwfRFsZwV1qg13bXLNPl2bE9BvkGe/rdet+853JM4z9b0CZXkO97Thc8G+Dz+pety0yaTTAuJbzruW17mBk5RYXgPGaIhrDBql+UCb5IP1MTCdqv2jzjPI8VYYg+OnX1mW+EpLxkc9rmpyS/3Un3o8n7qk2Uadg1cnNRHS0I6wGi9ldFKU4R79sCUdiXOghtjYWel0AMfVxRk/cO3+RkraExqgBTbFWiSdtA7KkN/plW0C8dqnrTnBhu03ZZgj3+y5dn3qfEdC+6RTn/bsH/2nPdu376Tpr4afqJvctMmkMRGIV8eWVAMCjIMJdBITNxGeowPUQDUW8yWfkZMOPGOrf3tgXxL6w7jJYzxAv7Is8VVfyaM+7WD06HJLffXgqtNAOxcW6bT3TqQmor1gX4wdJ1JRJ1C3GueqXln+jNjnSva7xrUf7EsnnqQWuS4JxLVtSbunzY5sE4h3/ctyGcex2zbpzK9+pPqXSraTZJt1nQlp5qW/Gn5Sdbtpk8FomESMyQlCXOKGpE4iZV2kTEjn4HQCOEXqO5EYa3XUGBEG4TPq83hGln8G+fyKTo5+Oy4hvtKSvDR6dFjVT9TDZ4J9APK7E+srk5p0oGPnQKmn5upW4+jmaTXLn5GVDtnvVbzalqQWt9if6PS7/GwTiHd9ynIZ58q8MKdcTed+y+lX35HQjn2t/QP8E2nkUTb91fCTqttNmwzgsBGWDYIyGpshTw91gnSOwO5PHhtXQrsEDADjtP0K/dCQzK/Py5MUbT2Drq8JY6OfdVzEV1qaB45xVT+xLIG4MH+0/Y4LIzXpqLpJaqRuNY6toZ1OM239bHRjhBznKr7SKLW4xf4S7B7tKtkmEO/6lOUyzrV7rv7Ft9ik8x1JtpnPwp/glxw7edVfDT+p2t68ySSU6SZRcoLAiQGNoC5UJhBj1CBtIzcj36hoI59RnwduNBjCM6jPr+DYGWOnzeqNKzdn691S3zI80xM40JaL7N1ITTq0r4qaQmqbcZ0M2q3m6iysdMhxruIrjVILyuQziGujHdhglpdsE4h3fcpyGaef3c+fgH2n3cPKdySkOZYswxgIQBp5atXp9elUbe/eZNwk0vlX6iQyEaTBqr7pbgre5ymBBW67+Yz6PMnye3PtORg9/XFcbLIE4quTEFq4kDBq2rilvnp48tYxutHRxrvBOLfw1Fmhnra5sintiLR6ODobKx1ynDWuY62HEum0YP0SiGtfHbTH5lzJNoF4178sl3Hmc3WAdI0k9hvqsyUPYGhiGa7UcbzEfcaqD59M1fbmTcZNIXf1FXUSmTjrdKcMcALzdJKTzqSmg6U9n1GfpyPQMT+DfL7ozHH2bLRq6KZL/7oFKJSx/xizzuBa/dQjF6MLh/Bui6Pqj9bqr910zpB09ILULePYE5pzn+XPiH2uuJYcl2Mgji1oo93bQTpo1ymakp52LWn3lNVuk2wTiGefjNvfVZxn8HyuwFyRV9e9NlB9R0I6OlGG+pZRF/tM++qwepv6ZKq2N28yGCJ5XKtRVaoBUZ56TBZXN4EKE0tdwXCYdNpyk8p+kEfb9XmWoT2Nb2/y+WI/6KcLD4ijRU3vwDFQlvGr+7X6qQf5xNEBPdCeQP1nafMMqv7pKNCpc3RAvjaXumUcR0Jb4HyclaqD6JSxyVxnpnnt1jZpaMi4XW/cr+zP9ii/csK1Tcpnn4znPGQcaJv6BMbHnNvmVr+4Uq6O1XVBGeaZMqB23KMd95A6Dj/JOYIv/ZvMXnQT34ExnI0jdbsFFh2LS4h3C/FV2VN/2vaNWodzVrb61q0tyus0P4FrvgONOp26tFv91adRbfA0m4xvLa/KmR0PoK+nRsK7LZA99fcEC2w2vlWfkXt1oPwnbTKP4tX91Z5UGzzNJsOr75kX7zWO0u0e/HmBxfFur/l76s/plzc/tON65s35Xh0oPz/53M+r+6s9qTZ4qp/LXpnR7VhG/wujw3A0s8nsxOh2LKP/hdFhOJrZZHZidDuW0f/C6DAczWwyOzG6Hcvof2F0GI5mNpmdGN2OZfS/MDoMRzObzE6Mbscy+l8YHYajuWmTmTBhwoQJE74aknmTeRCj27GM/hdGh+FoZpPZidHtWEb/C6PDcDSzyezE6HYso/+F0WE4mtlkduKVdKOv81mZ9+RVdeATLWf68G394vNwO1W3uzYZ/x5Jwr1h9Tl18AON6dwwKj48yLe0tuq+Alu67QXf0OJbWjw7v7Ccfx6gg/Lv9lHElf7X7M6vK78LR9hhRfsj3KIvdnw2mzz717bPTNXt5k0Gh4XR1HyNg8CC7mCBs6AtK6TxoTn/5smZjOxeVrrtCXPi5uIpUK2Ba6fpq2vd0em/sjs2GA81K41elT3sEB3vaVc/YD2uldrm2f7sBDaxh5afQNXtpk0GwdkMOuGvTYSnbZwgZV3QeW88T+OvxjUdHo2nv7o40dDTI9dO05yHd6Hqv7I7HCD3bsq5UXfQjhDP+zNSdbiVrbF16/5WqNe9zdzSZu3TM7X/zpg/narbXT+XdcLfMxGUdbFf22QwTE/kGFc+xzxOpDoL0nxF9+TElXK0S+Ce/C2n8lVWOvgGyDMZx9a4KEuep+za/8S3v0rW52DgsxLqOQ9oyHPoi89Rx2cu6u+y0h9yvIw1y640Io35oCyaaPvZFlfy0NByR5NjS0hn7DXOOLFJ0phz15O4KRuwCWyPegTbWUEdNE66Nrlmn6hjPjqrsdpD5wes1/383vmIxDVAfa9AWZ7DPW1sreHh1zb4kE2GwIK8BuXSSDAOjKH7ucxnadSUBcobZ7Jd2J7oyceIwDYwPAzbRUGbj4bnVLKvXOnHtXHlSbv2PzGP8eeiIY22gCv3FdKoT1A/N0OgHtq+Et04xfFC1WRLI7TRNpkb5kQHo3PhSjrxOkdH0I0FSFeDGk8b7dYxZW2X8WpvarNaT5Qhv9Ml2wTitU/qbR7rQOfOvNlv/YDzwLXrU+cjEtonnfq0Z//of86zfSct1/BwQd3k25sMIiM2k88kbeEECZPHpBJqXfIoT/vp9JhQ47RVjSX7mMYAlNUZP5qqC2RfuXK/NS41ML/2P9E5UoYxMTbKkUZelqlYhjlj4ZjmYqFNN59XoRunkMeYoGqypZF1Ms6Ve+YnbS/LHEk3FliNh7j2gi3qxBPHDG4c2Jr2VtcU6bRDnvZdyTaBeNe/LJfxzg+4trTpFdlOkm1eWztc6xoeLlTdvr3JiKcMJppyhoS6maZjZbLIq8aK4ZDP6cp6lCOdZ3HN/mBctGkadTJ/tYgeQT5H6J8LOI3W9NW4iKNF7X9ie7nY1bF7ZkJa9g24z03mljfTM9GNU8hT56rJlkY5N8adEw9IkmWOpBsLrMaT8ZUWjhlqGeJpR4lOv8vPNoF416csl3GurheupnO/5fSrj0hyTdT+Ab6INPIoW33TcKHq9rBNRuPzashTBfdOiA6RKxCvGwCnaQJGgcEC5TqjxSlrYJSB2l+cscbxaPI5kn1VF2BMGOe1cd2itxC3fPfMhDRCvq2gG9qg0SsunG6cQp7jqZpsaWSdjKsxoBfzh+2p3dF0Y4HVeDK+0iLHXMsQJ20FNoY2lWwTiHd9ynIZ59o9t/qVpPMRSbaZz2JeWauOnbzONw0XqrYP3WQ6Y0qcILCt3GRq27aZ7RKvm4SbB21lH7v+mvZoh1CfA6RptKkP/fcEJt24uv5LzSPuIvKZPqdCWTYSri4QF5KL8NVY6QTkoRdU3bY0ss6qvnOKs+mc2hHk2JLVeDKeNprUMecziGtvHdpZJdsE4l2fslzGu/Ui2C+2nKx8REKaY8kyjIEApJGnVp1en07V9mGbTDexFScIcIjc5yZTFzt5pOeJ2xNEYluQfVz1l7RHO4XuOejhQkh97G8dl4YsW3qrDYuHQJwNg3bcJGivagWUpW309pn2ifRHa/MMVjqB4wI04t437HQgSdbJOFefRT2cDdpd+3eAZ2HfKqvxENexMp5uDeeYtZO0O9JW0F63iWebQLzrX5bLOHbd2Ta4NhL7DfXZkgcsNLEMV+o4XuKdbxouVG2/tckgOmJzZUcnfwsnCKzDZDphGrs4qXlisQ84C/K5Wp+FzkIhnmWFfAJp1H0k+Ryh3y5aro7PPuS4yEMP+sV4oPa/QnnKsoBcyNQhTjtcOwdAm5SzfXWhPe4Jr7Z4tnRyvIIu6I1GjHlLoxpXM6AN4oZ8xlHYt4oO1P7n2Jhr1hFadG8H6aDRjLh2p80m2q8bel3XkG0C8eyTcfu7iqcfAOyYvLpZrnxEQjo6UYb6llEX+0z76tDp9elUbe/aZKph5GTcIjblaEOIM6ku+g7azzrAs5h4AhMOLBTa50p7GEHtr2VWz/oO+RyhD/YHA07ou4tRNH7L1v5XqK9+2ZbteCqrkKem1KUcmqqbG44L9xXY0inHC+pG+spus07Gc06wTbQCNEezo7FvFZ0y9phryjSvzH+FNPRifK4r7gnVhsH2KL/St7ZJ+Wt6ZxyqH2AubHOrX1wpV8eq3VOGNUEZUDvu0U6f0/mm4dc2eNcmcwSdMaxwwR/B2XS7FxeWsBC7hXpWnq0/2qCR6IiOZqsP3TqivE7zE7jmI9Co06lLu8c3fRLVBk+9yXCS9jRxds6k21fwlAYsnFdbQM/WH9v0FA5s0PVt9Qju1YHyn7TJPIpX8k3PptrgqTcZXofPsHBv4Uy6fQVOeJzMcZwsnlf7GeAI/fnZVb2w0zNsyvfqQPn5yed+Xsk3PZtqg6f/uexVGN2OZfS/MDoMRzObzE6Mbscy+l8YHYajmU1mJ0a3Yxn9L4wOw9HMJrMTo9uxjP4XRofhaGaT2YnR7VhG/wujw3A0N20yEyZMmDBhwldDMm8yD2J0O5bR/8LoMBzN1U1mGIZhGB7FbDLDMAzDTvzyy/8HkoYHRJJnBM4AAAAASUVORK5CYII=" /></p><p>لا ينبغي بك أخذ هذا الدواء لأكثر من 5 أيّام لمنع الغثيان والتقيّؤ المتأخّرين اللذين قد يحصلان بعد المعالجة الكيميائيّة.</p><p>&nbsp;</p><p>ليست أقراص بريمبيران 10 ملغ مناسبة للاستعمال لدى الأطفال الذين يقلّ وزنهم عن 30 كلغ. يجب استعمال أشكال صيدلانيّة أخرى (المحلول الفموي مثلاً).&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>عدد مرّات الاستعمال</strong></p><p>يجب عليك أن تنتظر 6 ساعات على الأقلّ بين كلّ جرعة، حتّى في حال حصول تقيّؤ أو رفض الجرعة لتفادي فرط الجرعة.</p><p><strong>المرضى المسنّون</strong></p><p>قد يتعيّن تخفيض الجرعة، حسب مشاكل الكلى أو الكبد والصحّة بصورة عامة.</p><p>قد تكون أشكال صيدلانيّة أخرى مناسبة أكثر للاستعمال لدى فئة المرضى هذه.</p><p><strong>البالغون المصابون بمشاكل كلويّة</strong></p><p>تحدّث إلى الطبيب إذا كنت تعاني من مشاكل كلويّة. يجب تخفيض الجرعة إذا كنت تعاني من مرض معتدل الحدّة أو حاد في الكلى.</p><p>قد تكون أشكال صيدلانيّة أخرى مناسبة أكثر للاستعمال لدى فئة المرضى هذه.</p><p><strong>البالغون المصابون بمشاكل كبديّة</strong></p><p>تحدّث إلى الطبيب إذا كنت تعاني من مشاكل كبديّة. يجب تخفيض الجرعة إذا كنت تعاني من مرض معتدل الحدّة أو حاد في الكبد.</p><p>قد تكون أشكال صيدلانيّة أخرى مناسبة أكثر للاستعمال لدى فئة المرضى هذه.</p><p><strong>الأطفال والمراهقون</strong></p><p>لا ينبغي استعمال أقراص بريمبيران 10 ملغ القابلة للتجزئة لدى الأطفال ما دون السنة من العمر (راجع القسم 2).</p><p><strong>إذا أخذت كميّة بريمبيران أكثر مما ينبغي</strong></p><p>اتصل بالطبيب أو الصيدلي على الفور. قد تصاب بحركات غير طبيعيّة (اضطرابات خارج الهرميّة) وبنعاس وباضطرابات في الوعي وبتشوّش ذهنيّ وبهلوسات وبمشاكل في القلب. قد يصف طبيبك علاجًا لهذه العوارض عند الضرورة. &nbsp;</p><p><strong>إذا نسيت أخذ بريمبيران</strong></p><p>لا تأخذ جرعة مضاعفة للتعويض عن جرعة نسيت أخذها. إذا كان لديك أسئلة أخرى حول استعمال هذا الدواء، اطرحها على الطبيب أو الصيدلي.</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل الأدوية كلّها، يمكن أن يسبّب بريمبيران تأثيرات جانبيّة لا تصيب المرضى كلّهم.</p><p>أوقف العلاج واتصل بطبيبك أو بالصيدلي على الفور إذا أصبت بأيّ من العوارض التالية في خلال فترة أخذ هذا الدواء:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حركات غير طبيعيّة (غالبًا في الرأس أو العنق). قد تحصل هذه الحركات لدى الأطفال أو الشباب، بخاصة عند استعمال جرعات عالية. تحصل هذه العوارض بشكل عام عند بدء العلاج وقد تحصل حتّى بعد إعطاء جرعة واحدة. سوف تتوقّف هذه الحركات عند علاجها علاجًا مناسبًا.&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى، ارتفاع ضغط الدم، نوبات صرع، تعرّق، فرط إنتاج اللعاب. قد تكون هذه العوارض إشارات مرض يُسمّى متلازمة الذُهان الخبيثة.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكّة أو طفح جلدي، تورّم الوجه أو الشفتين أو الحلق، صعوبة في التنفّس، مما قد يدلّ على ارتكاس تحسسي قد يكون حادًا.</p><p>&nbsp;</p><p><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>التأثيرات الجانبيّة الشائعة جدًا (تصيب أكثر من مريض من أصل 10 مرضى)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بنعاس.</p><p>&nbsp;</p><p><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>التأثيرات الجانبيّة الشائعة (تصيب حتّى مريض واحد من أصل 10 مرضى)</strong></p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اكتئاب مع عوارض خفيفة إلى حادة تتضمّن أفكارًا انتحاريّة</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حركات غير طبيعيّة مثل التشنّجات اللاإراديّة والهزّ وحركات التواء أو تقلّص العضلات (تيبّس، تصلّب)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عوارض شبيهة بداء باركنسون (تصلّب، رعشة)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عصبيّة</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم (بخاصة عند الحقن في الوريد)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالضعف.</p><p>&nbsp;</p><p><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>التأثيرات الجانبيّة غير الشائعة (تصيب حتّى مريض واحد من أصل 100 مريض)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات هورمون في الدم يُسمّى برولاكتين مما قد يسبّب إنتاجًا للحليب لدى الرجال والنساء غير المرضعات</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام الدورة الشهريّة</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هلوسات</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات في الوعي</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بطء ضربات القلب (بخاصة عند الحقن في الوريد)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حساسيّة</p><p>&nbsp;</p><p><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>&nbsp;&nbsp;&nbsp;<strong>التأثيرات الجانبيّة النادرة (تصيب حتّى مريض واحد من أصل 1000 مريض)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشوّش ذهني</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات صرع (بخاصة لدى مرضى الصرع)</p><p>&nbsp;</p><p><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>التأثيرات غير المعروفة معدّل الحصول (لا يمكن تقديرها استنادًا إلى البيانات المتوافرة)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مستويات غير طبيعيّة من صباغ الدم مما قد يغيّر لون بشرتك</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تكوّن غير طبيعي للثديين (تثدّي)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنّجات عضليّة غير إراديّة بعد الاستعمال المطوّل، بخاصة لدى المرضى المسنّين</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى، ارتفاع ضغط الدم، نوبات صرع، تعرّق، فرط إنتاج اللعاب. قد تكون هذه العوارض إشارات مرض يُسمّى متلازمة الذُهان الخبيثة.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغييرات في النظم القلبي يمكن رؤيتها على مخطط كهربائيّة القلب</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توقّف القلب (بخاصة عند حقن الدواء)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صدمة (انخفاض حاد في ضغط القلب) (بخاصة عند حقن الدواء)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إغماء (بخاصة عند حقن الدواء في الوريد)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتكاس تحسسي قد يكون حادًا (بخاصة عند حقن الدواء في الوريد)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضغط دم مرتفع جدًا.&nbsp; &nbsp;</p><p>&nbsp;</p><p><strong>للإبلاغ</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>الأعراض</strong><strong> </strong><strong>الجانبیة</strong></p><p><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة</strong><strong> </strong><strong>العربیة</strong><strong> </strong><strong>السعودیة</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>المركز</strong><strong> </strong><strong>الوطني</strong><strong> </strong><strong>للتیقظ</strong><strong> </strong><strong>والسلامة</strong><strong> </strong><strong>الدوائیة</strong><strong>:</strong></p><p><strong>فاكس</strong><strong>: </strong><strong>٠٠٩٦٦١١٢٠٥٧٦٦٢</strong></p><p><strong>التواصل مع المركز الوطني للتیقظ والسلامة الدوائیة على +966-11-2038222 تحويلة 2317-2356-2340</strong></p><p><strong>الخط الساخن</strong><strong>: </strong>19999</p><p>npc.drug@sfda.gov.sa <strong>: </strong><strong>البرید</strong><strong> </strong><strong>الإلكتروني</strong></p><p>www.sfda.gov.sa/npc <strong>: </strong><strong>الموقع</strong><strong> </strong><strong>الإلكتروني</strong></p><p>KSA_Pharmacovigilance@sanofi.com <strong>: </strong><strong>سانوفي-التيقظ الدوائي</strong></p></td></tr></tbody></table><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احفظ هذا الدواء بعيدًا عن نظر الأطفال ومتناولهم.</p><p>&nbsp;</p><p>لا تستعمل بريمبيران بعد انقضاء تاريخ الصلاحيّة المدوّن على العلبة. يشير تاريخ انتهاء الصلاحيّة إلى اليوم الأخير من الشهر المذكور.</p><p>&nbsp;</p><p>يُحفظ الدواء في حرارة ما دون 30 درجة مئويّة.</p><p>&nbsp;</p><p>لا ترمِ أيّ أدوية مع مياه الصرف الصحّي أو النفايات المنزليّة. إسأل الصيدلي عن كيفيّة التخلّص من الأدوية التي لم تعد تستعملها، فمن شأن هذه الإجراءات حماية البيئة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>ماذا تحتوي أقراص بريمبيران 10 ملغ القابلة للتجزئة</strong></p><p><strong>المادة الفاعلة هي:</strong></p><p>هيدروكلوريد الميتوكلوبراميد..........................................................................................10.50 ملغ</p><p>الكميّة المعادلة لهيدروكلوريد الميتوكلوبراميد غير المائي..........................................................10.00 ملغ</p><p>للقرص الواحد القابل للتجزئة.</p><p>&nbsp;</p><p><strong>المكوّنات الأخرى هي:</strong></p><p>لاكتوز وحيد التميّه، سلولوز دقيق البلوريّة، نشا الذرة، سيليكا غروانيّة لامائيّة، ستيارات المغنيزيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            كيف هو شكل أقراص بريمبيران 10 ملغ القابلة للتجزئة ومحتويات العلبة
يأتي هذا الدواء على شكل أقراص قابلة للتجزئة. 

علبة من 20 أو 40 أو 150. 

قد لا تكون أحجام العلب كلّها مسوّقة في بلدك. 

        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>حامل رخصة التسويق</strong></p><p>sanofi-aventis France</p><p>82, avenue Raspail</p><p>94250 Gentilly,</p><p>France</p><p>&nbsp;</p><p><strong>المصنّع</strong></p><p>Delpharm Dijon</p><p>6, boulevard de l&rsquo;Europe</p><p>21800 Quetigny&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>France</p><p>&nbsp;</p><p>التغليف الثانوي</p><p>Sanofi Aventis Arabia Co, Ltd.</p><p>Industrial Valley Phase 1A St. KAEC,, King Abdullah Industrial Valley Phase 1A St. KAEC,, Abdullah Economic City, Rabigh, 21423, Saudi Arabia</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            10/2016
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Primperan 10 mg scored tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Metoclopramide hydrochloride………………………………………………………………………10.50 mg (equivalent in anhydrousmetoclopramide hydrochloride…………………………………………10.00mg)
for one scored tablet.
Excipient: lactose.
For a full list of excipients, see Section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Scored tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For use in adults only.<br />Symptomatic treatment of nausea and vomiting including delayed nausea and vomiting induced by antimitotic agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For use in adults only. Oral use.<br />One tablet contains 10 mg of anhydrous metoclopramide hydrochloride.<br />Delayed nausea and vomiting not induced by antimitotic agents:<br />&frac12; to 1 tablet per dose, 3 times daily, before meals, allowing an interval of at least 6 hours between doses.<br />Delayed nausea and vomiting induced by antimitotic agents:<br />0.5 mg/kg/dose, 4 times daily, i.e. 1 tablet for 20 kg body weight per dose, allowing an interval of at least 6 hours between doses.<br />Treatment for periods of more than 3 months should be avoided (see Section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                This medicinal product must never be used in the following situations:
• Children under 18 years of age,
• Hypersensitivity to metoclopramide or to any of the other ingredients.
• Potentially hazardous stimulation of gastrointestinal motility in patients with gastrointestinal bleeding, mechanical obstruction or gastrointestinal perforation.
• History of tardive dyskinesia induced by neuroleptics or metoclopramide.
• Known or suspected pheochromocytoma (except when used for provocative tests); serious hypertensive events have been reported with dopamine antagonists including certain benzamides in this patient group.
• In combination with antiparkinsonian agents (levodopa, dopaminergic agonists and selegiline - see Section 4.5 Interaction with other medicinal products and other forms of interaction).
• Known history of methemoglobinemia with metoclopramide or of NADH-cytochrome b5 reductase deficiency.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Warnings<br />Primperan is a dopamine antagonist. It may cause neurological undesirable effects, such as extrapyramidal syndrome in particular in young adults and/or when the maximum dosage is exceeded. It is therefore recommended to comply with the dosage determined on the basis of patient weight and to respect an interval of at least six hours between doses (see Sections 4.2 Posology and method of administration and 4.8 Undesirable effects).<br />An interval of at least 6 hours must be allowed between doses, even in the event of vomiting and partial or total rejection of the dose.<br />These reactions generally occur at the beginning of treatment, between 1 and 3 hours after the last dose. They may occur after a single dose. If extrapyramidal symptoms occur, treatment with metoclopramide should be discontinued. These effects are generally fully reversible on treatment discontinuation, however, symptomatic treatment may be necessary (benzodiazepines in children, benzodiazepines and/or anticholinergic antiparkinsonian agents in adults).<br />Long-term treatment with Primperan may cause potentially irreversible tardive dyskinesia, particularly in elderly subjects. The risk of tardive dyskinesia increases with the duration of exposure and the cumulative dose administered. Treatment for periods of more than 3 months should be avoided. Treatment must be discontinued if clinical signs of tardive dyskinesia appear (see Section 4.8 Undesirable effects).<br />As a neuroleptic malignant syndrome has been reported in exceptional cases, treatment must be immediately discontinued if the patient develops unexplained hyperthermia or hyperthermia associated with other symptoms of malignant syndrome (pallor, autonomic disorders, impaired consciousness,muscle rigidity).<br />In the event of profuse vomiting, it is essential to prevent the risk of dehydration. Patients can generally be rehydrated orally using &ldquo;sweet-saline&rdquo; solutions (oral rehydration solution) given in small quantities at regular intervals.<br />Cases of methemoglobinemia, possibly due to NADH-cytochrome b5 reductase deficiency, have been reported. If this occurs, treatment must be immediately and permanently discontinued, and appropriate measures implemented.<br /><br />This medicinal product contains lactose. It should not be used in patients with galactose intolerance, Lapp lactase deficiency, or glucose and galactose malabsorption syndrome (rare hereditary diseases).<br />Precautions for use<br />Use of this medicinal product is not recommended in epileptic patients (increased frequency and severity of seizures).<br />In patients with renal or hepatic insufficiency, it is advisable to reduce the dosage.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Contraindicated combinations<br />+ Dopaminergic agents including non-antiparkinsonians and levodopa: mutual antagonism between dopaminergic agents or levodopa and neuroleptics.<br />An antiemetic with no extrapyramidal effects should be used.<br />+ MAO-B inhibitors (selegiline): mutual antagonism between selegiline (dopaminergic agent) andmetoclopramide (antiemetic neuroleptic).<br />An antiemetic with no extrapyramidal effects should be used.<br />Inadvisable combinations<br />+ Alcohol: potentiation of the sedative effects induced by neuroleptic drugs. Impaired alertness maymake it dangerous to drive and use machines.<br />Patients should not consume alcoholic beverages or medicinal products containing alcohol.<br />Combinations to be taken into consideration<br />+ Antihypertensive drugs: increased risk of hypotension, particularly postural (additive effect).<br />+ Nitrates, nitrites and related drugs: increased risk of hypotension, particularly postural.<br />+ Other sedative drugs: many drugs or substances can have additive depressant effects on the central nervous system and contribute to a decrease in alertness. These drugs include morphine derivatives (analgesics, antitussives, and replacement therapies), neuroleptics, barbiturates, benzodiazepines, non-benzodiazepine anxiolytics (such as meprobamate), hypnotics, sedative antidepressants (amitriptyline, doxepin, mianserin, mirtazapine, trimipramine), sedative H1- antihistamines, centrally-acting antihypertensives, baclofen, pizotifen and thalidomide: increased central nervous system depression. Impaired alertness may make it dangerous to drive and use machines.<br />+ Beta-blockers: vasodilator effect and risk of hypotension, particularly postural (additive effect).<br />+ Prilocaine: risk of additive methemoglobinemic effects, particularly in newborns.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />Considering the available data, metoclopramide can be used during pregnancy.<br />In patients receiving high-dose metoclopramide treatment at the end of pregnancy, and by analogy with other neuroleptics, a potential extrapyramidal syndrome cannot be ruled out in newborn infants. This should be taken into account when monitoring neonates in this setting.</p><p>Lactation<br />Women may breast-feed provided that treatment is occasional, for example, in cases of post- cesarean vomiting, and that the infant was born at term and in good health. Breast-feeding is not recommended in the event of premature birth, or long-term or high-dose treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Drivers and machine operators must be made aware of the risk of drowsiness related to use of this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The undesirable effects are listed by System-Organ Class. Undesirable effects have been ranked by frequency using the following convention: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1 000 to &lt; 1/100); rare (&ge; 1/10 000 to &lt; 1/1 000) and very rare (&lt; 1/10 000), frequency not known (cannot be estimated from the available data).</p><p>System Organ Class<br />Frequency<br />Undesirable effect<br />Blood and lymphatic system disorders<br />Frequency not known<br />Methemoglobinemia, possibly due to NADH- cytochrome b5 reductase deficiency, particularly in neonates (see section 4.4) Sulfhemoglobinemia, mainly with concomitant administration of high doses of sulfate-releasing medicinal products<br />Cardiac disorders<br />Uncommon<br />Bradycardia, particularly with the intravenous forms<br />Frequency not known<br />Cardiac arrest, occurring shortly after administration by injection, and possibly following on from bradycardia (see section 4.4);<br />atrioventricular block, sinus arrest particularly with<br />the intravenous route; QT interval prolongation on ECG; torsades de pointes<br />Endocrine disorders*<br />Uncommon<br />Amenorrhea, hyperprolactinemia<br />Rare<br />Galactorrhea<br />Frequency not known<br />Gynecomastia<br />Gastrointestinal disorders<br />Common<br />Diarrhea<br />General disorders and administration site conditions<br />Common<br />Asthenia<br />Immune system disorders<br />Uncommon<br />Hypersensitivity<br />Frequency not known<br />Anaphylactic reaction (including anaphylactic shock) particularly with the intravenous route<br />Nervous system disorders<br />Very common<br />Drowsiness<br />Common<br />Extrapyramidal disorders (particularly in children and young adults and/or when the recommended<br />dose is exceeded, even following administration of a single dose) (see section 4.4), parkinsonism, akathisia<br />Uncommon<br />Dystonia, dyskinesia, consciousness disorders<br />Rare<br />Seizures, especially in epileptic patients<br />Frequency not known<br />Tardive dyskinesia which may be persistent, during or after long-term treatment, particularly in elderly<br />patients (see section 4.4), neuroleptic malignant<br />syndrome (see section 4.4)<br />Psychiatric disorders<br />Common<br />Depression with mild to severe symptoms including suicidal ideation<br />Uncommon<br />Hallucination<br />Rare<br />Confusional state<br />Vascular disorders<br />Common<br />Hypotension, particularly with the intravenous forms.<br />Frequency not known<br />Shock, syncope after use of the injection form. Hypertensive crisis in patients with<br />pheochromocytoma (see section 4.3)<br />* Endocrine disorders during long-term treatment in relation to hyperprolactinemia (amenorrhea, galactorrhea, gynecomastia).<br />The following effects, sometimes in combination, usually occur when high doses are used:<br />&ndash; Extrapyramidal symptoms: acute dystonia and dyskinesia, parkinsonism, akathisia, including after administration of a single dose of the medicinal product, particularly in children and young adults (see section 4.4).<br />Drowsiness, consciousness disorders, confusion, hallucinations.<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />- The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2340.<br />o Reporting hotline : 19999<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br />&bull; Sanofi- Pharmacovigilance: KSA_Pharmacovigilance@sanofi.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms<br />Extrapyramidal symptoms, drowsiness, consciousness disorders, confusion, hallucinations, hypertensive crisis, and even cardiorespiratory arrest may occur.<br />Management of overdose:<br />Treatment of extrapyramidal symptoms, whether or not related to overdose, is only symptomatic (benzodiazepines in children, and/or anticholinergic antiparkinsonian medicinal products in adults).<br />Symptomatic treatment and continuous monitoring of cardiovascular and respiratory function should be implemented, depending on clinical condition.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: PROPULSIVES.<br />ATC code: A03FA01<br />(A: Alimentary tract and metabolism)<br />Metoclopramide is a dopaminergic antagonist neuroleptic. It prevents vomiting by blocking dopamine sites.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Metoclopramide is rapidly absorbed in the gastrointestinal tract. Bioavailability is generally 80% but inter-individual variability related to the first pass liver effect has been found.<br />Distribution<br />Metoclopramide is extensively distributed in tissue. The volume of distribution is 2.2 to 3.4 l/kg. Plasma protein binding is low. The drug crosses the placental barrier and is excreted in breast-milk.<br />Metabolism<br />Metoclopramide undergoes slightmetabolism.<br />Excretion<br />Metoclopramide is mainly excreted in the urine in the unbound or sulfoconjugated form. The elimination half-life is 5 to 6 hours. The half-life increases in patients with kidney or liver failure.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose monohydrate, microcrystalline cellulose, maize starch, anhydrous colloidal silica, magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>20, 40 or 150 scored tablets in heat-formed (PVC/aluminum) blister packs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific precautions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SANOFI-AVENTIS FRANCE
1-13 boulevard Romain Rolland 75014 Paris
France
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                October 2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>